Robert Z. Orlowski, M.D., Ph.D.

Peer-Reviewed Articles

1. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, and Qazilbash MH.. Outcomes of autologous stem cell transplant in patients with ultra high-risk multiple myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
2. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, and Richardson PG.. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10(10):e825-e837, 2023. e-Pub 2023. PMID: 37708911.
3. Setayesh SM, Ndacayisaba LJ, Rappard KE, Hennes V, Rueda LYM, Tang G, Lin P, Orlowski RZ, Symer DE, Manasanch EE, Shishido SN, and Kuhn P.. Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma. NPJ Precis Oncol. e-Pub 2023. PMID: 37723227.
4. Li N, Lin P, Zuo Z, You MJ, Shuai W, Orlowski R, Manasanch EE, Li S, Xu J, Garces S, Jelloul FZ, Tang Z, Wang W, Medeiros LJ, and Yin CC.. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Med 12(13):14293-14304, 2023. e-Pub 2023. PMID: 37212518.
5. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, and Qazilbash MH.. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578. e-Pub 2023. PMID: 37461327.
6. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, and Manasanch EE.. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047, 2023. PMID: 37311413.
7. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, and Qazilbash MH.. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873. e-Pub 2023. PMID: 37376789.
8. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, Perrot A, Weisel K, Raje N, Macro M, Frenzel L, Leleu X, Wang J, Rampelbergh RV, Uhlar CM, Vermeulen J, Duran J, Borgsten F, and Usmani SZ.. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma. Future Oncol 9(13):887-889, 2023. PMID: 37212642.
9. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2022. PMID: 35605883.
10. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
11. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23(4):279-290, 2023. e-Pub 2022. PMID: 36797154.
12. Ray U, and Orlowski RZ.. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. Pharmaceuticals (Basel) 16(4), 2023. e-Pub 2023. PMID: 37111346.
13. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 41(8):JCO2200940, 2023. e-Pub 2023. PMID: 36599114.
14. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther 29(3):174.e1-174.e10, 2023. e-Pub 2022. PMID: 36494017.
15. Dicanio M, Giaccherini M, Clay-Gilmour A, Macauda A, Sainz J, Machiela MJ, Rybicka-Ramos M, Norman AD, Tyczynska A, Chanock SJ, Barington T, Kumar SK, Bhatti P, Cozen W, Brown EE, Suska A, Haastrup EK, Orlowski RZ, Dudzinski M, Garcia-Sanz R, Kruszewski M, Martinez-Lopez J, Beider K, Iskierka-Jazdzewska E, Pelosini M, Berndt SI, Razny M, Jamroziak K, Rajkumar SV, Jurczyszyn A, Vangsted AJ, Collado PG, Vogel U, Hofmann JN, Petrini M, Butrym A, Slager SL, Ziv E, Subocz E, Giles GG, Andersen NF, Mazur G, Watek M, Lesueur F, Hildebrandt MAT, Zawirska D, Ebbesen LH, Marques H, Gemignani F, Dumontet C, Várkonyi J, Buda G, Nagler A, Druzd-Sitek A, Wu X, Kadar K, Camp NJ, Grzasko N, Waller RG, Vachon C, Canzian F, Campa D. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer 152(2):239-248, 2023. e-Pub 2022. PMID: 36082445.
16. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
17. Ndacayisaba LJ, Rappard KE, Shishido SN, Setayesh SM, Tang G, Lin P, Matsumoto N, Hsu CJ, Nevarez R, Velasco CR, Naghdloo A, Yang E, Kelly K, Hicks J, Mason J, Orlowski RZ, Manasanch EE, Kuhn P. Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci 23(21), 2022. e-Pub 2022. PMID: 36362214.
18. Macauda A, Clay-Gilmour A, Hielscher T, Hildebrandt MAT, Kruszewski M, Orlowski RZ, Kumar SK, Ziv E, Orciuolo E, Brown EE, Försti A, Waller RG, Machiela MJ, Chanock SJ, Camp NJ, Rymko M, Razny M, Cozen W, Várkonyi J, Piredda C, Pelosini M, Belachew AA, Subocz E, Hemminki K, Rybicka-Ramos M, Giles GG, Milne RL, Hofmann JN, Zaucha JM, Vangsted AJ, Goldschmidt H, Rajkumar SV, Tomczak W, Sainz J, Butrym A, Watek M, Iskierka-Jazdzewska E, Buda G, Robinson DP, Jurczyszyn A, Dudzinski M, Martinez-Lopez J, Sinnwell JP, Slager SL, Jamroziak K, Reis RMV, Weinhold N, Bhatti P, Carvajal-Carmona LG, Zawirska D, Norman AD, Mazur G, Berndt SI, Campa D, Vachon CM, Canzian F. Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiol Biomarkers Prev 31(9):1863-1866, 2022. e-Pub 2022. PMID: 35700034.
19. Torres HA, Angelidakis G, Jiang Y, Economides M, Mustafayev K, Yibirin M, Orlowski R, Champlin R, Verstovsek S, Raad I. Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine (Baltimore) 101(37):e30608, 2022. PMID: 36123927.
20. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
21. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
22. Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov 3(4):OF1-OF12, 2022. e-Pub 2022. PMID: 35653112.
23. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
24. Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC, DETERMINATION Investigators. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med 387(2):132-147. e-Pub 2022. PMID: 35660812.
25. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
26. Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck A. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol 33(100416):1-13, 2022. e-Pub 2022. PMID: 35242510.
27. Ndacayisaba LJ, Rappard KE, Shishido SN, Ruiz Velasco C, Matsumoto N, Navarez R, Tang G, Lin P, Setayesh SM, Naghdloo A, Hsu CJ, Maney C, Symer D, Bethel K, Kelly K, Merchant A, Orlowski R, Hicks J, Mason J, Manasanch EE, Kuhn P. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol 29(5):2954-2972, 2022. e-Pub 2022. PMID: 35621632.
28. Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood 139(9):1289-1301, 2022. e-Pub 2021. PMID: 34521108.
29. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2021. PMID: 34686083.
30. Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SM. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia 24(1):1-11, 2022. e-Pub 2021. PMID: 34826777.
31. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
32. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
33. Wang X, Shirazi F, Yan W, Liu X, Wang H, Orlowski RZ, Wang H. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. J Cell Mol Med 25(21):10164-10174, 2021. e-Pub 2021. PMID: 34651428.
34. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22(11):1582-1596, 2021. e-Pub 2021. PMID: 34655533.
35. Wang XS, Shi Q, Mendoza TR, Garcia-Gonzalez A, Chen TY, Kamal M, Chen TH, Heijnen C, Orlowski RZ, Cleeland CS. Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer 29(10):6099-6107, 2021. e-Pub 2021. PMID: 33792800.
36. Belachew AA, Wu X, Callender R, Waller R, Orlowski RZ, Vachon CM, Camp NJ, Ziv E, Hildebrandt MAT. Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiol 73:101972, 2021. e-Pub 2021. PMID: 34216957.
37. Lee HC, Feng L, Oriabure O, Graham V, Chen W, Badillo M, Lu R, Lee HJ, Jain P, Manasanch EE, Orlowski RZ, Wang ML. A phase 1 trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 96(7):E243-E246, 2021. e-Pub 2021. PMID: 33811767.
38. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
39. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia 23(4):361-374, 2021. e-Pub 2021. PMID: 33735664.
40. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2020. PMID: 33781521.
41. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
42. Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Jeffrey Medeiros L, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol 34(2):327-335, 2021. e-Pub 2020. PMID: 32908255.
43. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
44. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
45. Kamal M, Wang XS, Shi Q, Zyczynski TM, Davis C, Williams LA, Lin HK, Garcia-Gonzalez A, Cleeland CS, Orlowski R. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer 29(1):467-475, 2021. e-Pub 2020. PMID: 32390093.
46. Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ, SWOG1211 Trial Investigators. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 8(1):e45-e54, 2021. e-Pub 2020. PMID: 33357482.
47. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. J Clin Oncol 39(3):JCO2001370, 2021. e-Pub 2020. PMID: 33326255.
48. Li Z, Liu H, He J, Wang Z, Yin Z, You G, Wang Z, Davis RE, Lin P, Bergsagel PL, Manasanch EE, Wong STC, Esnaola NF, Chang JC, Orlowski RZ, Yi Q, Yang J. Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metab 33(1):78-93.e7, 2021. PMID: 33406405.
49. Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res 11(6):3285-3293, 2021. e-Pub 2021. PMID: 34249462.
50. Kaufman JL, Mina R, Shah JJ, Laubach JP, Nooka AK, Lewis C, Gleason C, Sharp C, Harvey RD, Heffner LT, Richardson P, Lonial S, Orlowski RZ. Phase 1 trial evaluating vorinostat plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 20(12):797-803, 2020. e-Pub 2020. PMID: 32819881.
51. Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med 17(11):e1003323, 2020. e-Pub 2020. PMID: 33147277.
52. Dhodapkar MV, Sexton R, Hoering A, Van Rhee F, Barlogie B, Orlowski R. Race-dependent differences in risk, genomics and Epstein-Barr virus exposure in monoclonal gammopathies: Results of SWOG S0120. Clin Cancer Res 26(22):5814-5819, 2020. e-Pub 2020. PMID: 32816893.
53. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
54. Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, Peters ES, Pawlish K, Bock C, Van Den Berg DJ, Rand KA, Stram D, Conti DV, Auclair D, Colditz GA, Mehta J, Haiman CA, Terebelo H, Janakiraman N, Singhal S, Chiu B, Vij R, Bernal-Mizrachi L, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Cozen W, Ailawadhi S. Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States. JCO Oncol Pract 16(10):JOP1900639, 2020. e-Pub 2020. PMID: 32469686.
55. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation: Updated data in high-risk newly diagnosed multiple myeloma patients. Blood Adv 4(19):4834-4837, 2020. PMID: 33027527.
56. Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(10):1317-1330, 2020. e-Pub 2020. PMID: 32866432.
57. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10(9):91, 2020. e-Pub 2020. PMID: 32887873.
58. Shirazi F, Jones RJ, Singh RK, Zou J, Kuiatse I, Berkova Z, Wang H, Lee HC, Hong S, Dick L, Chattopadhyay N, Orlowski RZ. Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. Proc Natl Acad Sci U S A 117(33):20004-20014, 2020. e-Pub 2020. PMID: 32747568.
59. Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren EM, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie B, Orlowski RZ. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res 26(15):3969-3978, 2020. e-Pub 2020. PMID: 32299820.
60. Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZ. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. J Mol Med (Berl) 98(8):1161-1173, 2020. e-Pub 2020. PMID: 32632752.
61. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood 136(8):936-945, 2020. e-Pub 2020. PMID: 32325490.
62. Jones RJ, Singh RK, Shirazi F, Wan J, Wang H, Wang X, Ha MJ, Baljevic M, Kuiatse I, Davis RE, and Orlowski RZ.. Intravenous immunoglobulin G suppresses Heat shock protein (HSP)-70 expression and enhances the activity of HSP90 and proteasome inhibitors. Front Immunol, 2020. e-Pub 2020. PMID: 32903557.
63. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, and Dabaja BS.. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
64. Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM. The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types. Cancer 126(14):3192-3201, 2020. e-Pub 2020. PMID: 32401342.
65. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2019. PMID: 31786242.
66. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 105(5):e242-e245, 2020. e-Pub 2019. PMID: 31413094.
67. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
68. Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med 9(9):2989-2996, 2020. e-Pub 2020. PMID: 32108443.
69. Manasanch EE, Jain P, Chen W, Oriabure O, Badillo M, Feng L, Berkova Z, Orlowski RZ, Wang M. Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. Am J Hematol. e-Pub 2020. PMID: 32390148.
70. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol 38(11):JCO1901740, 2020. e-Pub 2019. PMID: 31652094.
71. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2019. PMID: 31881283.
72. Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J 10(2):17, 2020. e-Pub 2020. PMID: 32054831.
73. Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv 4(1):181-190, 2020. PMID: 31935283.
74. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94(12):E319-E322, 2019. e-Pub 2019. PMID: 31489991.
75. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leuk Lymphoma 60(14):1-8, 2019. e-Pub 2019. PMID: 31282244.
76. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
77. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
78. Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol 186(5):e117-e121, 2019. e-Pub 2019. PMID: 31090915.
79. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
80. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
81. Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk 9(8):522-530, 2019. e-Pub 2019. PMID: 31160237.
82. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune and genomic analysis. Blood Adv 3(15):2400-2408, 2019. e-Pub 2019. PMID: 31405950.
83. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative radiotherapy for multiple myeloma of long bones: Should the entire rod be treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
84. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: Autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2018. PMID: 30446740.
85. Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 15(6):459-473, 2019. e-Pub 2019. PMID: 31104525.
86. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
87. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ, MAIA Trial Investigators, the MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380(22):2104-2115, 2019. PMID: 31141632.
88. Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med 11(494), 2019. e-Pub 2019. PMID: 31142679.
89. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, and Manasanch EE.. Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569. e-Pub 2019. PMID: 31160237.
90. Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood 133(14):1572-1584, 2019. e-Pub 2019. PMID: 30737236.
91. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski RZ, Feng L, and Manasanch EE.. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma 60(4):964-970, 2019. PMID: 30227761.
92. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 33(4):1058-1059, 2019. PMID: 30842604.
93. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2018. PMID: 30548467.
94. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):442-452, 2019. e-Pub 2018. PMID: 30032678.
95. Kunacheewa C, Orlowski RZ. New drugs in multiple myeloma. Annu Rev Med 70(1):521-547, 2019. e-Pub 2019. PMID: 30691369.
96. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2018. PMID: 30300461.
97. Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ. Targeting Myddosome signaling in Waldenström’s macroglobulinemia with the Interleukin-1 receptor-associated kinase 1/4 inhibitor R191. Clin Cancer Res 24(24):6408-6420, 2018. e-Pub 2018. PMID: 30126942.
98. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib-lenalidomide-dexamethasone with panobinostat for the frontline treatment of transplant-eligible multiple myeloma patients. Lancet Haematol 5(12):e628-e640, 2018. e-Pub 2018. PMID: 30501870.
99. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
100. Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32(10):2224-2239, 2018. e-Pub 2018. PMID: 29581547.
101. Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8(7):67, 2018. e-Pub 2018. PMID: 29980678.
102. Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma 59(6):1364-1374, 2018. e-Pub 2017. PMID: 28937327.
103. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A.. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124(12):2561-2569, 2018. PMID: 29723393.
104. Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS. Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma. Clin Pharmacokinet 57(4):529-538, 2018. e-Pub 2017. PMID: 28983805.
105. Nair S, Joel Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Leif Bergsagel L, Dirk Hose D, Flavell RA, Mistry PK, EMeffre E, Dhodapkar MV.. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 3(8):pii: 98259. e-Pub 2018. PMID: 29669929.
106. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):515-518, 2018. e-Pub 2017. PMID: 28673185.
107. Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32(2):353-363, 2018. e-Pub 2017. PMID: 28745330.
108. Steiner RE, Orlowski RZ, Lee HC. Acute pancreatitis associated with ixazomib in a multiple myeloma patient. Acta Haematol 139(1):67-70. e-Pub 2018. PMID: 29402766.
109. Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118(3):388-397, 2018. e-Pub 2017. PMID: 29241222.
110. Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252-262, 2018. e-Pub 2017. PMID: 29257139.
111. Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S. A phase 1 and 2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer 123(23):4617-4630, 2017. e-Pub 2017. PMID: 28817190.
112. Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE, Yang L, Orlowski RZ. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget 8(69):113858-113873. e-Pub 2017. PMID: 29371952.
113. Yang J, Liu Z, Liu H, He J, Yang J, Lin P, Wang Q, Du J, Ma W, Yin Z, Davis E, Orlowski RZ, Hou J, Yi Q. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Sci Signal 10(509), 2017. e-Pub 2017. PMID: 29233917.
114. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol 179(3):503-506, 2017. e-Pub 2016. PMID: 27378601.
115. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30(10):1378-1386, 2017. e-Pub 2017. PMID: 28664940.
116. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327-1337, 2017. e-Pub 2017. PMID: 28843768.
117. Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by up-regulation of Bim in multiple myeloma. Neoplasia 19(10):772-780, 2017. e-Pub 2017. PMID: 28863346.
118. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
119. Robinson D, Orlowski RZ, Stokes M, He J, Huse S, Chitnis A, Kranenburg B, Lam A. Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol 99(2):119-132, 2017. e-Pub 2017. PMID: 28306169.
120. Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol 178(4):547-560, 2017. e-Pub 2017. PMID: 28466536.
121. Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Donna M. Weber DM, and Orlowski RZ.. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8(43):73723-73732, 2017.
122. Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8(35):59476-59491, 2017. e-Pub 2017. PMID: 28938651.
123. Vogl DT, Raje NS, Jagannath S, Richardson PG, Hari P, Orlowski RZ, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, and Lonial S.. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 23(13):3307-3315, 2017. e-Pub 2017. PMID: 28053023.
124. Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14(7):417-433, 2017. e-Pub 2017. PMID: 28117417.
125. Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 17(7):424-432, 2017. e-Pub 2017. PMID: 28655599.
126. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo P, Ruvolo VR, Pecot CV, Amadori D, Aruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski RZ, Plunkett W, Lichtenberg T, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Hagop K, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2016. PMID: 27903673.
127. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional structural chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single institution experience. Mod Pathol 30(6):843-853, 2017. e-Pub 2017. PMID: 28281554.
128. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
129. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
130. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
131. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell 32(1):88-100. e-Pub 2017. PMID: 28669490.
132. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
133. Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE, Orlowski RZ. RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. Br J Haematol 177(1):80-94, 2017. e-Pub 2017. PMID: 28369725.
134. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BG, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18(4):e206-e217, 2017. e-Pub 2017. PMID: 28368259.
135. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2016. PMID: 27862330.
136. Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH. Clinical and pathological characteristics of HIV- and HHV8- negative Castleman disease. Blood 129(12):1658-1668, 2017. e-Pub 2017. PMID: 28100459.
137. Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519-527, 2017. e-Pub 2016. PMID: 28017406.
138. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci. Cancer Epidemiol Biomarkers Prev 25(12):1609-1618, 2016. e-Pub 2016. PMID: 27587788.
139. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
140. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
141. Orlowski RZ, Lonial S.. Integration of novel agents into the care of patients with multiple myeloma. Clin Cancer Res 22(22):5443-5452. e-Pub 2016. PMID: 28151712.
142. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
143. Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle Through Phosphoinositide 3-kinase Signaling and Ikaros Expression. Clin Cancer Res 22(19):4901-4912, 2016. e-Pub 2016. PMID: 27297582.
144. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
145. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(14):1319-1331, 2016. PMID: 27705267.
146. Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim JC. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1534-1538, 2016. e-Pub 2016. PMID: 26887657.
147. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer 122(13):2050-6, 2016. e-Pub 2016. PMID: 27191689.
148. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24):2955-2962, 2016. e-Pub 2016. PMID: 27002115.
149. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 57(5):1-27, 2016. e-Pub 2015. PMID: 26421453.
150. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30(5):1005-17, 2016. e-Pub 2015. PMID: 26710887.
151. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34(13):1544-57, 2016. e-Pub 2016. PMID: 26976420.
152. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
153. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551-1560, 2016. e-Pub 2016. PMID: 26778538.
154. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology 68(4):482-91, 2016. e-Pub 2015. PMID: 26118455.
155. Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona A. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol 172(6):889-901, 2016. e-Pub 2016. PMID: 26914976.
156. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2016. PMID: 26871714.
157. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
158. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res 22(1):34-43, 2016. e-Pub 2015. PMID: 26561559.
159. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27-38, 2016. e-Pub 2015. PMID: 26671818.
160. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2015. PMID: 26702475.
161. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 4:90, 2016. e-Pub 2016. PMID: 28018601.
162. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 21(12):2039-51, 2015. e-Pub 2015. PMID: 26428082.
163. Li B, Fu J, Chen P, Ge X, Li Y, Kuiatse I, Wang H, Wang H, Zhang X, Orlowski RZ. The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediates Bortezomib Resistance in Multiple Myeloma. J Biol Chem 290(50):29854-68, 2015. e-Pub 2015. PMID: 26483548.
164. Voorhees PM, Orlowski RZ, Mulkey F, Watson P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD, Larson RA. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171(3):373-7, 2015. e-Pub 2015. PMID: 26202857.
165. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
166. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma. Blood 126(20):2284-90, 2015. e-Pub 2015. PMID: 26384354.
167. Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B. Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy. Blood 126(22):2475-8, 2015. e-Pub 2015. PMID: 26468228.
168. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 6(33):34329-34341. e-Pub 2015. PMID: 26455377.
169. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29(9):1945-8, 2015. e-Pub 2015. PMID: 25721897.
170. Cheah CY, Orlowski RZ, Manasanch EE, Oo TH. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol 94(9):1605-7, 2015. e-Pub 2015. PMID: 26044891.
171. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 33(26):2863-9, 2015. e-Pub 2015. PMID: 26240224.
172. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1413-7, 2015. e-Pub 2015. PMID: 25842049.
173. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk 15(8):472-476, 2015. e-Pub 2015. PMID: 25963284.
174. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373(7):621-31, 2015. e-Pub 2015. PMID: 26035255.
175. Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastritis E, Dimopoulos MA, Shah J. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma 56(6):1723-1726, 2015. e-Pub 2014. PMID: 25284489.
176. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
177. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56(5):1335-1341, 2015. e-Pub 2014. PMID: 25248883.
178. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
179. Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121(7):1138-46, 2015. e-Pub 2014. PMID: 25469832.
180. Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J. Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6(11):8567-78, 2015. PMID: 25895124.
181. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56(3):1-18, 2015. e-Pub 2014. PMID: 24844357.
182. Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136(5):991-1002, 2015. e-Pub 2014. PMID: 25042852.
183. Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res 39(3):371-9, 2015. e-Pub 2015. PMID: 25612941.
184. Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia 17(3):289-300, 2015. PMID: 25810013.
185. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2014. PMID: 25107338.
186. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 29(2):515, 2015. PMID: 25651464.
187. Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ 22(1):96-107, 2015. e-Pub 2014. PMID: 25168239.
188. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 100(1):100-6, 2015. e-Pub 2014. PMID: 25261096.
189. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špicka I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 90(1):42-9, 2015. e-Pub 2014. PMID: 25294016.
190. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8(1):74, 2015. e-Pub 2015. PMID: 26104577.
191. Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J 5:e334, 2015. e-Pub 2015. PMID: 26252787.
192. Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun 6:8428, 2015. e-Pub 2015. PMID: 26455434.
193. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
194. Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3(5):1275-83, 2014. e-Pub 2014. PMID: 24913924.
195. Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib-resistance in multiple myeloma through a novel link between autophagy and apoptosis. Blood 124(17):2687-97, 2014. e-Pub 2014. PMID: 25208888.
196. Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol 34(18):3435-49, 2014. e-Pub 2014. PMID: 25002530.
197. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 2014. e-Pub 2014. PMID: 24887378.
198. Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu G. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res 38(8):896-900, 2014. e-Pub 2014. PMID: 24939217.
199. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 2014. e-Pub 2014. PMID: 24921909.
200. San Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Goh YT, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123(26):4136-4142, 2014. e-Pub 2014. PMID: 24833354.
201. Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20(12):3174-86, 2014. e-Pub 2014. PMID: 24727327.
202. Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ, Madan A, Avet-Loiseau H, Chopra R. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD® therapy. Leukemia 28(5):1129-31, 2014. e-Pub 2013. PMID: 24166296.
203. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123(14):2204-8, 2014. e-Pub 2014. PMID: 24425802.
204. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 2014. e-Pub 2014. PMID: 24419515.
205. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366-74, 2014. e-Pub 2014. PMID: 24423611.
206. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28(3):525-42, 2014. e-Pub 2013. PMID: 24253022.
207. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2014. e-Pub 2013. PMID: 23760401.
208. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7(1):127-41, 2014. e-Pub 2013. PMID: 24350987.
209. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587-600, 2014. e-Pub 2014. PMID: 24419113.
210. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269-77, 2014. e-Pub 2013. PMID: 23974982.
211. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 55(1):11-8, 2014. e-Pub 2013. PMID: 23614765.
212. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78-85, 2014. e-Pub 2013. PMID: 24144643.
213. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5):632-9, 2014. e-Pub 2013. PMID: 24335104.
214. Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One 9(3):e89064, 2014. e-Pub 2014. PMID: 24594907.
215. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 2014. PMID: 24886772.
216. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 2014. PMID: 25181509.
217. Zhang L, Morris JS, Zhang J, Orlowski RZ, Baladandayuthapani V. Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics. Cancer Inform 13(Suppl 2):113-23, 2014. e-Pub 2014. PMID: 25520554.
218. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12):2351-6, 2013. e-Pub 2013. PMID: 23670297.
219. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 2013. e-Pub 2013. PMID: 24117234.
220. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 24(6):791-805, 2013. PMID: 24332045.
221. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant 48(12):1537-42, 2013. e-Pub 2013. PMID: 23852321.
222. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
223. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122-8, 2013. e-Pub 2013. PMID: 24014245.
224. Orlowski RZ. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 40(5):634-51, 2013. PMID: 24135408.
225. Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZ. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther 346(3):381-92, 2013. e-Pub 2013. PMID: 23820125.
226. Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk Suppl 2:S317-329, 2013. e-Pub 2013. PMID: 23988451.
227. Orlowski RZ. Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell 24(3):275-7, 2013. PMID: 24029222.
228. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
229. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 2013. e-Pub 2013. PMID: 23432640.
230. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 2013. PMID: 23627452.
231. Lee HC, Shah JJ and Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013(1548-8748):302-306, 2013. PMID: 23714530.
232. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27(4):780-91, 2013. e-Pub 2012. PMID: 23288300.
233. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19(8):2248-56, 2013. e-Pub 2013. PMID: 23447001.
234. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12(6):459-62, 2012. e-Pub 2012. PMID: 23009979.
235. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 72(24):6393-402, 2012. e-Pub 2012. PMID: 23066034.
236. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 2012. e-Pub 2012. PMID: 22833546.
237. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 11(10):2243-53, 2012. e-Pub 2012. PMID: 22933706.
238. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
239. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 12(5):310-8, 2012. PMID: 23040437.
240. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 2012. e-Pub 2012. PMID: 22425892.
241. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Orlowski RZ, and Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol 158(6):739-748, 2012. e-Pub 2012. PMID: 22845873.
242. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: ten years later. Blood 120(5):947-59, 2012. e-Pub 2012. PMID: 22645181.
243. Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors up-regulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 72(16):4225-37, 2012. e-Pub 2012. PMID: 22693249.
244. Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiang Y, Gao L, An G, Yang N, Orlowski RZ, Yang L. The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol 44(7):1166-73, 2012. e-Pub 2012. PMID: 22531714.
245. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49(3):258-62, 2012. PMID: 22726549.
246. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. e-Pub 2011. PMID: 22015451.
247. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 2012. e-Pub 2012. PMID: 22555973.
248. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2011. PMID: 21887685.
249. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119(16):3668-83, 2012. e-Pub 2012. PMID: 22275381.
250. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
251. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119(13):3003-3015, 2012. e-Pub 2012. PMID: 22271445.
252. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥ 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2011. PMID: 21780997.
253. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26(1):149-157, 2012. e-Pub 2011. PMID: 21799510.
254. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, and Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22(3):345-358. e-Pub 2012. PMID: 22975377.
255. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595-608. e-Pub 2011. PMID: 22193964.
256. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon (CRBN) expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118(18):4771-9, 2011. e-Pub 2011. PMID: 21860026.
257. Orlowski RZ. The future of proteasome inhibitors in relapsed/refractory multiple myeloma. Oncology (Williston Park) 25(12 Suppl 2), 2011. PMID: 25188482.
258. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 2011. e-Pub 2011. PMID: 21437886.
259. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. e-Pub 2011. PMID: 21844567.
260. Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 117(16):3758-62, 2011. e-Pub 2011. PMID: 21328327.
261. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311-21, 2011. e-Pub 2011. PMID: 21724551.
262. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group. International Myeloma Working Group (IMWG) consensus approach to the treatment of myeloma patients who are candidates for autologous stem-cell transplantation. Blood 117(23):6063-73, 2011. e-Pub 2011. PMID: 21447828.
263. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase (ALP) variation during carfilzomib treatment is associated to best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 2011. e-Pub 2011. PMID: 21477075.
264. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus Panel 1. Consensus recommendations for uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 152(18):579-592, 2011. e-Pub 2011. PMID: 21292775.
265. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(13):11009-20, 2011. e-Pub 2010. PMID: 21189262.
266. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2011. e-Pub 2010. PMID: 21057542.
267. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-592, 2011. e-Pub 2011. PMID: 21241278.
268. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11(3):285-95, 2011. PMID: 21247387.
269. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44-9, 2011. PMID: 21454189.
270. Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-158, 2011. e-Pub 2010. PMID: 21062912.
271. Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 10(6):465-470, 2010. PMID: 21147690.
272. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, Orlowski RZ. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89(11):1133-1140, 2010. e-Pub 2010. PMID: 20532504.
273. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-2452, 2010. e-Pub 2010. PMID: 20805315.
274. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 24(10):1700-1712, 2010. e-Pub 2010. PMID: 20811404.
275. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Droger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127, 2010. PMID: 20410922.
276. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23(11):1964-1979, 2009. e-Pub 2009. PMID: 19741722.
277. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147(4):515-525, 2009. e-Pub 2009. PMID: 19775297.
278. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085-7091, 2009. e-Pub 2009. PMID: 19903785.
279. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10):1716-1730, 2009. e-Pub 2009. PMID: 19494840.
280. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA and Durie BM. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23(9):1545-1556, 2009. e-Pub 2009. PMID: 19421229.
281. Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you?. Blood 113(23):5695-5696, 2009. PMID: 19498025.
282. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145(4):481-490, 2009. e-Pub 2008. PMID: 19344406.
283. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113(19):4667-4676, 2009. e-Pub 2008. PMID: 19050304.
284. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2009. e-Pub 2009. PMID: 19436606.
285. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensingeer W, Comenzo RL, Kuman S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, SanMiguel J, Ludwig H. Hajek R, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadora M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV and Durie BG, with the IMWG.. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23(10):1904-1912, 2009. PMID: 19494840.
286. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63(1):99-107, 2008. e-Pub 2008. PMID: 18327587.
287. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8(6):352-355, 2008. PMID: 19064400.
288. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14(17):5416-5425, 2008. PMID: 18765533.
289. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112(7):1529-1537, 2008. PMID: 18300257.
290. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649-1657, 2008. PMID: 18347166.
291. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111(9):4690-4699, 2008. e-Pub 2008. PMID: 18305219.
292. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, Hussein MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414-423. e-Pub 2007. PMID: 18094721.
293. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892-3901. e-Pub 2007. PMID: 17679727.
294. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464-2472. e-Pub 2007. PMID: 17515569.
295. Voorhees PM, Orlowski RZ. Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S156-162, 2007. PMID: 17562254.
296. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Su CM, Demo SD, Bennett MK, Van Leeuwen FWB, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110(9):3281-3290, 2007. e-Pub 2007. PMID: 17591945.
297. Voorhees PM, Chen Q, Kuhn DJ, Kuhn DJ, Small GW, Hunsucker, SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 13(21):6469-6478, 2007. PMID: 17975159.
298. Small GW, Shi YY, Higgins LS and Orlowski RZ. Mitogen-activated protein kinasse phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67(9):4459-4466, 2007. PMID: 17483361.
299. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, and Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol 5(10 Suppl 15):7-19, 2007. PMID: 18000495.
300. Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 24(4):234-237, 2006. PMID: 16948177.
301. Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107(11):2688-2697, 2006. PMID: 17075878.
302. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86(3):211-216. e-Pub 2006. PMID: 17146676.
303. Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 100(1):33-47, 2006. e-Pub 2006. PMID: 16807678.
304. Voorhees PM, Orlowski RZ. Emerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma 7(1):33-41, 2006. PMID: 16879768.
305. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113-3120. e-Pub 2006. PMID: 16754936.
306. Orlowski RZ, Zeger EL. Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Investig Drugs 15(2):117-130, 2006. PMID: 16433592.
307. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1):51-61, 2006. PMID: 16401713.
308. Orlowski RZ. The proteasome inhibitor bortezomib. Nat Clin Pract Oncol 3:16-17, 2006. PMID: 16407873.
309. Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2(1):121-135, 2006. PMID: 16556079.
310. Ryan DP, O'Neil BH, Supko JG, Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Kusack JC, Jr. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107(11):2688-2697, 2006. e-Pub 2006.
311. Orlowski RZ. Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?. Nat Clin Pract Oncol 3(1):16-17, 2006. PMID: 16407873.
312. Orlowski RZ. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematology Am Soc Hematol Educ Program:338-347, 2006. PMID: 17124081.
313. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106(12):3777-3784, 2005. e-Pub 2005. PMID: 16099887.
314. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105(8):3058-3065, 2005. e-Pub 2004. PMID: 15626743.
315. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103(6):1195-1200, 2005. PMID: 15690325.
316. Ramaswamy B, Povoski S, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendear K, Somasundaram S, Orlowski RZ, Shapiro CL. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 93(1):67-74, 2005. PMID: 16184461.
317. Orlowski RZ. The ubiquitin-proteasome pathway from bench to bedside. Hematology 2005:220-225, 2005. PMID: 16304384.
318. Orlowski RZ. Bortezomib therapy following first relapse. Oncology (Huntingt.) 19(1):23-26, 2005. PMID: 15743149.
319. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66(6):1478-1490, 2004. e-Pub 2004. PMID: 15448190.
320. Orlowski RZ. Bortrezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Comp Cancer Net 2 Suppl 4:S16-20, 2004. PMID: 19791424.
321. Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma 45(11):2215-2219, 2004. PMID: 15512809.
322. Orlowski RZ. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 4(2):171-179, 2004. PMID: 15056047.
323. Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma 45(1):187-188, 2004. PMID: 15061219.
324. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42 MAPK. J Pharmacol Exp Ther 307(3):861-869, 2003. e-Pub 2003. PMID: 14557375.
325. Richardson PG, Barlogie B, Berenseon J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanina R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Esseltine D-L, Kauffman M, Schenkein DP and Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 2003. e-Pub 2003. PMID: 12826635.
326. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 9(17):6316-6325, 2003. PMID: 14695130.
327. Orlowski RZ, Dees EC. Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5(1):1-7, 2003. e-Pub 2002. PMID: 12559038.
328. van Deventer HW, Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, Shea TC. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Am J Hematol 71(3):184-190, 2002. PMID: 12410573.
329. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420-4427, 2002. PMID: 12431963.
330. Orlowski RZ, Baldwin AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8(8):385-389, 2002. PMID: 12127724.
331. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277(31):27864-27871, 2002. e-Pub 2002. PMID: 12023956.
332. Small GW, Chou TY, Dang CV, Orlowski RZ. Evidence for involvement of calpain in c-Myc proteolysis in vivo. Arch Biochem Biophys 400(2):151-161, 2002. PMID: 12054425.
333. Somasundaram S, Edmund, NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62(13):3868-3875, 2002. PMID: 12097302.
334. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60(21):6178-6183, 2000. PMID: 11085542.
335. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6(4):303-313, 1999. PMID: 10381632.
336. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58(19):4342-4348, 1998. PMID: 9766662.
337. Orlowski R. Epstein-Barr Virus Nuclear Antigen Number One: Cloning, Purification and Aspects of Function. Ph.D. Dissertation, 1991.
338. Orlowski R, Miller G. Single stranded structures are present within plasmids containing the Epstein-Barr virus latent origin of replication. J Virol 65(2):677-686, 1991. PMID: 1846191.
339. Orlowski R, Polvino-Bodnar M, Hearing J, and Miller G. Inhibition of specific binding of EBNA 1 to DNA by murine monoclonal and certain human polyclonal antibodies. Virology 176(2):638-642, 1990. PMID: 2161154.
340. Orlowski R, Miller G. Topological effects of EBNA 1 on ori P. Advances in Experimental Medicine and Biology: Immunobiology and Prophylaxis of Human Herpesvirus Infections 278:115-124, 1990. PMID: 1963028.
341. Orlowski M, Orlowski R, Chang JC, Wilk E, Lesser M. A sensitive procedure for determination of cathepsin D: Activity in alveolar and peritoneal macrophages. Mol Cell Biochem 64(2):155-162, 1984. PMID: 6150434.

Invited Articles

1. Orlowski RZ. The expanding role of proteasome inhibition in multiple myeloma: An update from ASH. Myeloma Today 6, 2005.
2. Orlowski RZ. Emerging options for initial induction therapy of patients with multiple myeloma. Clin Advances in Hematologic Malignancies 1(2):9-12, 2005.
3. Orlowski RZ. Drug resistance: Overcoming multiple myeloma drug resistance by inhibiting the proteasome. Myeloma Today 5:7:20-23, 2004.
4. Orlowski RZ. Proteasome inhibition and multiple myeloma: Current concepts and future directions. Amer J Oncol Rev 3:(6):12-15, 2004.

Abstracts

1. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 138(Suppl 1):3941, 2021.
2. Anderson, LD Jr., Kaufman JL, Laubach JP, Sborov DW, Reeves R, Rodriguez C, Chari A, Silbermann RW, Costa LJ, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. Blood 138(Suppl 1):2723, 2021.
3. Chhabra S, Callander NS, Costa LJ, Kaufman JL, Laubach JP, Douglas W. Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann RW, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees PM. Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. Blood 138(Suppl 1):2852, 2021.
4. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood 138(Suppl 1):482, 2021.
5. Choudhary RK, Jones RJ, Kuiatse I, Wang H, Vega F, Bouska AC, Lone WG, Iqbal J, Orlowski RZ. A Novel Antibody Drug Conjugate (ADC) Targeting Cell Surface Heat Shock Protein 70 (csHSP70) Is Active Against Pre-Clinical Models of Peripheral T-Cell Lymphoma (PTCL). Blood 138(Suppl 1):870, 2021.
6. Liyasova M, Migdal N, McDonald Z, Yang L, Ma B, Piza JG, Reece DE, Manasanch EE, Orlowski RZ, Trudel S, Kaufman GP. M-Protein Sequencing and Monitoring in Serum of LC-Only Multiple Myeloma Patients. Blood 138(Suppl 1):4729, 2021.
7. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EE, Olsem JB, Morphey AN, Huo XJ, Bashir Q, Thomas SK, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients. Blood 138(Suppl 1):4774, 2021.
8. Perrot A , Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis NJ, Basu S, Nahi H, Hulin C, Quach H, Go Mldschmidt H, O'Dwyer ME, Venner CP, Weisel K, Mace JR, Raje NS, Tiab M, Macro, Frenzel L, Leleu X, Liu K, Fastenau J, Gries KS, Ho KF, Mistry P, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. Blood 138(Suppl 1):4095, 2021.
9. Laubach JP, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann RW, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees PM. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood 138(Suppl 1):79, 2021.
10. Usmani SZ, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis NJ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer ME, Perrot A, Venner CP, Weisel K, Mace JR, Raje NS, Tiab M, Macro M, Frenzel L, Leleu X, Pei H, Van Rampelbergh R, Tromp B, Delioukina M, Facon T. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. Blood 138(Suppl 1):1646, 2021.
11. Perrot A, Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis JN, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer ME, Venner CP, Weisel K, Mace JR, Raje NS, Tiab M, Macro M, Frenzel L, Leleu X, Liu K, Fastenau J, Gries KS, Ho KF, Mistry P, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. Blood 138(Suppl 1):1655, 2021.
12. Moreau P, Facon T, Usmani S, Dimopoulos M, Kumar S, Plesner T, Goldschmidt H, Reece D, Orlowski R, Aurore P, Leiba DR, Ravlei ME, Chari A, San-Miguel J, Cook G, Ida I, Bahlis N. Effect of Lenalidomide (R) ± Dexamethasone (d) Discontinuation on Daratumumab Efficacy in Multiple Myeloma (MM): Subgroup Analysis of the Phase 3 MAIA and POLLUX Studies. SOHO 2020 Virtual Poster Presentation, 2020.
13. Kumar SK, Baz RC, Orlowski RZ, Anderson LD Jr., Ma H, Shrewsbury A, Croghan KA, Bilgi M, Kansagra A, Kapoor P, Li Z, and Brayer J. Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 136(Suppl 1):133, 2020.
14. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA Nieto Y, Qazilbash MH, Berkova Z, Pei Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, and Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(Suppl 1), 2020.
15. Kaufman JL, Laubach JP, Sborov D, Reeves B, Rodriguez C, Chari A, Silbermann RW, Costa LJ, Anderson LD,Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Lutska Y, Bobba P, Pei H, Ukropec J, Vermeulen J, Lin TS, Richardson PG, and Voorhees PM. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood 136(Suppl 1), 2020.
16. Singh RK, Jones RJ, Shirazi FM, Zou JM, Wang H, Lee HC, Manasanch EE, Kuiatse I, Pahl A and Orlowski RZ. The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma. Blood 136(Suppl 1), 2020.
17. Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott EC, Hoering A, Durie BGM, Usmani SZ, and Orlowski RZ. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 136(Suppl 1), 2020.
18. Becnel MR, Horowitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, and Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136(1371), 2020.
19. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, and Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136(1394), 2020.
20. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136(1452), 2020.
21. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE and Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 136(1506), 2020.
22. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(1512), 2020.
23. Krishnan A, Hoering A, Hari P, Sexton R, and Orlowski RZ. Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803. Blood 136(1515), 2020.
24. Thomas SK, Cha S-C, Parshottam SR, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC, Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS and Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). Blood 136(2055), 2020.
25. Kumar SK, Facon T, Usmani SZ, Plesner T, Orlowski RZ, Touzeau C, Basu S, Bahlis N, Goldschmidt H, O'Dwyer M, Venner CP, Weisel K, Hulin C, Karlin L, Preis M, Broyl A, Renwick W, Hansson M, Krevvata M, Wang J, Van Rampelbergh R, Ukropec J, Uhlar CM, Kobos R and Perrot A. Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. Blood 136(2276), 2020.
26. Wong L, Lamba M, Jiménez Nuñez MD, Bauer D, Richardson PG, Bahlis N, Vangsted AJ, Ramasamy K, Trudel S, Martínez-Lopez J, Mateos M-V, 9, Rodriguez-Otero P, Lonial S, Popat R, Oriol A, Karanes C, Orlowski RZ, Berdeja JG, Pourdehnad M and Pierce DW. Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136(2295), 2020.
27. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE and Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 136(2413), 2020.
28. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE and Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(2419), 2020.
29. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE and Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood 136(2422), 2020.
30. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE and Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 136(2423), 2020.
31. Yeung EK, Primeaux BR, Horowitz SB, Shank BR, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM). Blood 136(3216), 2020.
32. Strassz A, Raab MS, Orlowski RZ, Kulke M, Schiedner G and Pahl A. A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma. Blood 136(3230), 2020.
33. Jakubowiak A, Jasielec J, Rosenbaum C, Orlowski RZ, Cohen A, Bensinger W, Anderson A, Dossett T, Iskander K, Mezzi K, Welliver T, Yusuf A, Durie B. Efficacy and safety of carfilzomib-pomalidomide-dexamethasone in relapsed and/or refractory multiple myeloma: pooled analysis of 2 single arm studies. 17th IMW 2019(OAB-049). e-Pub 2019.
34. Moreau P, Stewart AK, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Islander K, Mateos M-V. Poster - Once-Weekly (70 mg/m²) Versus Twice-Weekly (56 mg/m²) Dosing of Carfilzomib in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: A Post Hoc Analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 Trials. European Hematology Association (EHA), 2019. e-Pub 2019.
35. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Orlowski RZ, Bahlis NJ, Nahi H, Mollee P, Ramasamy K, Roussel M, Chaleteix C, Araujo C, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang J, Kobos R, McKay C, Gries KS, Trudeau J, Hulin C, Weisel K. Poster - Faster and Sustained Improvement in Health-related Quality of Life for Newly Diagnosed Multiple Myeloma (NDMM) Patients Ineligible for Transplant Treated With Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Rd Alone: MAIA. European Hematology Association (EHA), 2019. e-Pub 2019.
36. Hulin C, Facon T, Kumar S, Plesner T, Orlowski RZ, Touzeau C, Bahlis N, Basu S, Nahi H, Quach H, Goldschmidt H, O'Dwyer M, Cook G, Garderet L, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Chiu C, Krevvata M, Wang J, Van Rampelbergh R, Uhlar C, Kobos R, Qi M, Usmani SZ. Poster - Impact of Age on Efficacy and Safety of Daratumumab in combination With Lenalidomide and Dexamethasone (D-Rd) in Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM):MAIA. European Hematology Association (EHA), 2019. e-Pub 2019.
37. Bahlis N, Facon T, Usmani SZ, Kumar SK, Plesner T, Orlowski RZ, Touzeau C, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer ME, Venner CP, Weisel KC, Krevvata M, Pei H, Wang J, Van Rampelbergh R, Ukropec J, Uhlar CM, Kobos R, Perrot A. Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood 134(Suppl 1):1875, 2019.
38. Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann RW, Costa LJ, Anderson LD, Nathwani N, Shah ND, Efebera YA, Costello CL, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood 134(Suppl 1):691, 2019.
39. Kachuri L, Du Z, Weinhold N, Song G, Rand KA, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, John EM, Bernstein L, Stroup A, Zangari M, van Rhee F, Olshan A, Zheng W, Ingles SA, Press M, Carpt en JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Fiala MA, Terebelo HR, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC-H, Stram D, Vij R, Bernal-Mizrachi L, Morgan G, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti D, Haiman CA, Ziv E, Witte JS, Cozen W. Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood 134(Suppl 1):4379, 2019.
40. Nishimoto M, Zeng K, Huang M, Lyu M-A, Shah ND, Iyer SP, Orlowski RZ, Parmar S. Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation. Blood 134(Suppl 1):3095, 2019.
41. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood 134(Suppl 1):3198, 2019.
42. Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, Thomas SK, Iyer S, Mailankody S, Korde N, Amini B, Lin P, Berkova Z, Weber DM, Lei F, Lendvai N, Hildebrandt M, Neelapu SS, Orlowski RZ, Landgren O. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood 134(Suppl 1):3116, 2019.
43. Costello CL, Gregory TK, Ali SA, Berdeja JG, Patel KK, Shah ND, Ostertag E, Martin C, Ghoddusi M, Shedlock DJ, Spear MA, Orlowski RZ, Cohen AD. Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood 134(Suppl 1):3184, 2019.
44. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, and Usmani SZ. Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood 132(120737), 2018. e-Pub 2018.
45. Mateos M-V, Orlowski R, Siegel D, Reece D, Moreau P, Ocio E, Shah J, Rodriguez-Otero P, Munshi N, Avigan D, Ghori R, Marinello P, San Miguel J. Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma: Updated Safety and jEfficcy Analysis from Keynote-023. Abstract: EHA, Madrid, Spain, 2017.
46. Ocio EM, Mateos MV, Orlowski RZ, Siegel D, Reece DE, Moreau P, Rodriguez-Otero P, Munshi N, Avigan D, Ghori R, Wnek R, Mogg R, Marinello P, San Miguel J. Pembrolizumab Plus Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy and Biomarker Analyses. ASCO 2017 KN023 Poster, 2017.
47. Dimopoulos M-A, Moreau P, Nahi H, Plesner T, Goldschmidt H, Suzuki K, Orlowski R, Rabin N, Leiba M, Oriol A, Chari A, San Miguel J, Richardson P, Usmani S, Orourk L, Wu K, Casneu T, Chhiu C, Qin X, Bahlis NJ,. Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone (DRD) Versus RD Alone in Relapsed or Refractory Multiple Myeloma (RRMM): Updaate Analysis of Pollux. Haematology Society of Australia and New Zealand, Australian & New Zealand Society of Blood Transfusion, and Australasian Society of Thrombosis & Haemostasis (HAA)(JJD-62096). e-Pub 2017.
48. Bahlis NJ, Moreau P, Nahi H, Plesner T, Goldschmidt H, Suzuki K, Orlowski RZ, Rabin N, Leiba M, Oriol A, Chari A, San-Miguel J, Richardson PG, Usmani SZ, O’Rourke LM, Wu K, Casneuf T, Chiu C, Qin X, Dimopoulos MA. Daratumumab, Lenalidomide, and Dexamethasone (DRD) vs Lenalidomide and Dexamethasone (RD) in Relapsed or Refractory Multiple Myeloma (RRMM): Update on POLLUX. Haematocon (ISHBT), the 56th Annual Conference of the Indian Society of Haematology & Blood Transfusion 35:389. e-Pub 2017.
49. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Feng S, Kimball AS, Moreau P. Overall Survival of Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone versus Bortezobmib and Dexamethasone in the Randomized Phase 2 ENDEAVOR Trial. Selected Oral Abstract. Spanish Hematology Congress, Hotel Pullman, New Delhi Aerocity, 2017.
50. Van Laar ES, Orlowski RZ, Cameron D, Ressler SW, and Mikhael JR. Diagnosing and Managing Plasma Cell Disorders: Education Gaps in Primary Care Providers and Hematologist/Oncologists. Blood 130(1):5606, 2017. e-Pub 2017.
51. Zhou L, Zhang Y, Sampath D, Leverson JD, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, and Grant S. Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo. Blood 130(1):2540, 2017. e-Pub 2017.
52. Weisel KC, Siegel D, San Miguel JF, Hájek R, Ho PJ, Gaidano G, Orlowski RZ, Zhou L, Kimball AS, and Moreau P. Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study. Blood 130(1):1850, 2017. e-Pub 2017.
53. Heinz Ludwig, Andrew Spencer, Tibor Kovacsovics, Nashat Y. Gabrail, Leonard Minuk, Amy S. Kimball, Robert J. Pelham, Ying C. Ou, and Robert Z. Orlowski. Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study. Blood 130(1):3125, 2017. e-Pub 2017.
54. Jing Yang, Zhiqiang Liu, Huan Liu, Jin He, Jianling Yang, Pei Lin, Qiang WANG, Juan Du, Wencai Ma, Richard E Davis, Robert Z. Orlowski, Jian Hou, and Qing Yi. C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis. Blood 130(1):3043, 2017. e-Pub 2017.
55. Zou J, Jones RJ, Mertz JE, Wang H, Kuiatse I, Sullivan B, Fung L, Richard N, Erdman P, Torres E, Chourasia AH, Chan K WH, Mercurio F, Stirling DI, and Orlowski RZ. Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma. Blood 130(1):4418, 2017. e-Pub 2017.
56. Chaudhry M, Steiner R, Claussen CM, Patel K, Lee HC, Weber DM, Thomas SK, Feng C, Kramer M, Amini B, Orlowski RZ, Feng L, and Manasanch EE. Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia. Blood 130(1):1880, 2017. e-Pub 2017.
57. Manasanch EE, Lee HC, Pate KKl, Weber DM, Lee HJ, Thomas SK, Chen W, Oriabure O, Badillo M, Graham V, Lei F, McCarthy MS, Orlowski RZ, and Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood 130(1):3090, 2017. e-Pub 2017.
58. Thomas SK, Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng L, Amini B, Morphey A, Crumpton B, Phillips S, Miller C, Gonzalez M, and Orlowski RZ. Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 130(1):840, 2017. e-Pub 2017.
59. Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas, Donna M. Weber, Silvia C. Munoz, Ashley Morphey, Qaiser Bashir, Muzaffar H. Qazilbash, and Robert Z. Orlowski. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 130(1):437, 2017. e-Pub 2017.
60. Manasanch EE, Claussen CM, Dong W, Lee HC, Thomas SK, Patel KK, Reed VK, Dabaja BS, Milgrom S, Pinnix CC, Parmar S, Bashir Q, Qazilbash MH, Amini B, Raymond A, Orlowski RZ, Feng L, and Weber DM. A Clinical Model of Progression to Multiple Myeloma in Solitary Plasmacytoma. Blood 130(1):5367, 2017. e-Pub 2017.
61. Manasanch EE, Mathur R, Lee HC, Weber DM, Patel KK, Thomas SK, Munoz SC, Morales de Partovi C, Claussen CM, Lin P, Amini B, Wang L, MA MCJ, Qing Y, Lei F, Baladandayuthapani V, Davis RE, Neelapu SS, and Orlowski RZ. Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma. Blood 130(1):3089, 2017. e-Pub 2017.
62. Mathur R, Barnett BE, Hermanson D, He J, Zhang Z, Rengarajan S, Codde R, Wang X, Tan Y, Martin C, Smith J, Lee HC, Manasanch EE, Thomas SK, Patel KK, Weber DM, Davis RE, Orlowski RZ, Ostertag EM, Shedlock D, Yang J, and Neelapu SS. B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors. Blood 130(1):3068, 2017. e-Pub 2017.
63. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, and Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. Blood 130(1):4365, 2017. e-Pub 2017.
64. Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, Kerbauy LN, Lu J, Lim FLWI, Mendt MC, Depombo A, Daher M, Basar R, Neelapu SS, Orlowski RZ, Andreeff M, Marin DC, Champlin RE, Shpall EJ, and Rezvani K. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo. Blood 130(1):4454, 2017. e-Pub 2017.
65. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, and Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 130(1):399, 2017. e-Pub 2017.
66. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha S-C, Kim K, Popescu M, Shah N, Bashir Q, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr N, Garfall AL, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, and Kwak LW. Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 130(1):3193, 2017. e-Pub 2017.
67. Du Z, Weinhold N, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Hu D, Graff J, Berndt SI, Blot WJ, Carpten JD, Casey G, Stevens VL, Kittles R, Phyllis G, Hennis A, Klein EA, Nemesure B, Rybicki BA, Stanford J, Witte J, Ambrosone CB, John EM, Bernstein L, Stroup A, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Bandera E, Ingles SA, Mehta J, Colditz GA, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Le Marchand L, Anderson KC, Ziv E, Chiu BC-H, Conti D, Stram D, Vij R, Bernal-Mizrachi L, Zonder JA, Morgan GJ, Huff CA, Orlowski RZ, Lonial S, Haiman CA, and Cozen W. A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants. Blood 130(1):3058, 2017. e-Pub 2017.
68. Usmani SZ, Dimopoulos MA, Oriol A, Nahi H, San Miguel J, Bahlis N, Rabin N, Komarnicki M, Suzuki K, Plesner T, Samoilova O, Yoon S-S, Ben-Yehuda D, Richardson PG, Goldschmidt H, Reece D, Khokhar N, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Orlowski RZ. An Open-Label, Randomized, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRD) versus Lenalidomide and Dexamethasone (RD) in Patients (PTS) with Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. 2016 ASH Meeting on Hematologic Malignancies, 2016.
69. Brown N, Yang Y, Hwang M, Kavianpour B, Azadian M, Bernal-Mizrachi L, Zonder J, Nooka AK, Janakiraman N, Terebelo H, Mehta J, Vij R, Pawlish K, Chiu Brian C-H, Zimmerman T, Tomasson MH, Colditz GA, Stram DO, Peters ES, Haiman CA, Graff JJ, Kolonel L, Huff CA, Orlowski RZ, Lonial S, Cozen W, Ailawadhi S. Heterogeneity in Cytogenetic Testing for Multiple Myeloma Across the United States. ASH - Health Services Outcome, 2016.
70. Gragert L, Hwang A, Bernal-Mizrachi L, Ailawadhi S, Singhal S, Vanderberg DJ, Sheng X, Stram A, Conti DV, Rand KA, Song C, Graff JJ, Janakiraman N, Mehta J, Stram DO, Bock C, Kolonel L, Colditz GA, Mohrbacher A, Peters ES, Terebelo H, Nooka AK, Vij R, African Ancestry Breast and Prostate Consortium, Hari PN, Beksac M, Chiu Brian C-H, Tomasson MH, Zonder J, Huff CA, Orlowski RZ, Lonial S, Haiman CA, Cozen W. HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). ASH 2016 128(22):3250, 2016. e-Pub 2016.
71. Moreau P, Oriol A, San-Miguel J, Orlowski RZ, Plesner T, Goldschmidt H, Reece D, Khokhar N, Qin X, Dimopoulos MA. An Open-Label, Randomized, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRD) versus Lenalidomide and Dexamethasone (RD) in Patients (PTS) with Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. Brazilian Congress of Hematology, Hematology and Cell Therapy (HEMO). Florianopolis, Brazil, 2016.
72. Mateos M-V, Orlowski R, Siegel D, Reece D, Moreau P, Ocio E, Shah J, Rodriguez-Otero P, Munshi N, Avigan D, Ghori R, Marinello P, San Miguel J. Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma: Updated Safety and Efficacy Analysis From KEYNOTE-023. Annual Conference of Indian Society of Haematology & Blood Transfusion (ISHBT) in Jaipur, India, 2016.
73. Moreau P, Oriol A, Nahi H, San Miguel J, Bahlis NJ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Khokhar N, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Dimopoulos MA. An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide,a dn Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Repalsed or Refractory Multiple Myeloma (RRMM): POLLUX. Poster Presentation at The Indian Society of Haematology & Blood Transfusion (ISHBT) in Jaipur India, 2016.
74. Moreau P, Oriol A, Nahi H, San Miguel J, Bahlis NJ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Khokhar N, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Dimopoulos MA. An Open-label, Randomised Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. Poster Presentation at The 2016 Haematology Society of Australia and New Zealand Society of Blood Transfusion and the Australasian Society of Thrombosis and Haemostasis (HAA) in Melbourne, Australia, 2016.
75. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P. An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. Indian Society of Haematology & Blood Transfusion (ISHBT)-Haematocon 2016 in Jaipur, India, 2016.
76. Moreau P, Oriol A, San Miguel J, Orlowski RZ, Plesner T, Goldschmidt H, Reece D, Khokhar N, Qin X, Dimopoulos MA. An Open-Label, Randomized, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRD) versus Lenalidomide and Dexamethasone (RD) in Patients (PTS) with Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. The European School of Haematology (ESH). Milan, Italy, 2016.
77. Moreau P, Oriol A, Nahi H, San Miguel J, Bahlis NJ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Khokhar N, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Dimopoulos MA. An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRM): POLLUX. Poster Presentation at The Lymphoma & Myeloma: An International Congress on Hematologic Malignancies in New York, NY, 2016.
78. Moreau P, Oriol A, Nahi H, San Miguel J, Bahlis NJ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Samoilova OS, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Khokhar N, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Dimopoulos MA. An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX. Oral Presentation at The Lymphoma * Myeloma: An International Congress on Hematologic Malignancies in New York, NY, 2016.
79. Pang J, Shi Q, Liu Z, He J, Liu H, Lin P, Orlowski RZ, Cui J, and Yang J. Resistin Induces Multidrug Resistance in Myeloma By Inhibiting Cell Death and Upregulating ABC Transporter Expression. Blood 128(22):4476, 2016. e-Pub 2016.
80. Tu Y-S, He J, Liu H, Davis RE, Orlowski RE, Allen JE, and Yang J. ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma. Blood 128(22):4476, 2016. e-Pub 2016.
81. Ailawadhi S, Jacobus SJ, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder J, Crowley J, Hoering A, Barlogie B, Orlowski RZ, and Rajkumar SV. Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials. Blood 128(22):1192, 2016. e-Pub 2016.
82. Claussen CM, Lee H, Shah JJ, Richards T, Shah N, Patel K, Bashir Q, Parmar S, Thomas S, Nieto Y, Qazilbash MH, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, and Manasanch EE. Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 128(22):1192, 2016. e-Pub 2016.
83. Bashir Q, El Shazly M, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, and Qazilbash M. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood 128(22):3453, 2016. e-Pub 2016.
84. Zhuang J, Lee H, Kuiatse I, Wang H, Shirazi F, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Kreshock A, Tirrell S, Menon S, Jones RJ, and Orlowski RZ. The Anti-Tumor Effect of the Ubiquitin-Activating Enzyme (UAE) Inhibitor TAK-243 on Pre-Clinical Models of Multiple Myeloma. Blood 128(22):3296, 2016. e-Pub 2016.
85. Mohyuddin GR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, and Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 128(22):4613, 2016. e-Pub 2016.
86. Marchesini M, Ogoti Y, Fiorini E, D'anca M, Storti P, Nezi L, Samur MK, Gañán-Gómez I, Fulciniti M, Bohannan ZS, Clise-Dwyer K, Giuliani N, Munshi NC, Orlowski RZ, Garcia-Manero G, DePinho RA , and Colla S. ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood 128(22):359, 2016. e-Pub 2016.
87. Shah N, Thall PF, Milton DR, Bashir Q, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing C, Cornelison A, Delgado R, Shpall EJ, Orlowski RZ, Champlin RE, and Qazilbash M. Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. Blood 128(22):2269, 2016. e-Pub 2016.
88. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross BM, Honhar M, Cha S-C, Kim K, Rao SS, Popescu M, Shah N, Bashir Q, Patel K, Shpall EJ, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Kerr N DS, Garfall AL, Cohen AD, Dengel K, June CH, Champlin RE, and Kwak L. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 128(22):4548, 2016. e-Pub 2016.
89. Veltri LW, Milton DR, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski TZ, Shpall EJ, Champlin RE, Qazilbash MH, and Bashir Q. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood 128(22):4626, 2016. e-Pub 2016.
90. Robinson D Jr. Orlowski RZ, He J, Lam A, Zhao N, and Cakana AZ,. Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial. Blood 126(23):875, 2015.
91. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper L JN, MD PhD6, Lee DA, Parmar S, Cao K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K and Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. Blood 126(23):929, 2015.
92. Shah JJ, Feng L, Thomas SK, Weber D, Wang M, Manasanch EE, Mendoza K, and Orlowski RZ,. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23):376, 2015.
93. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155, 2015.
94. Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, and Dispenzieri A. Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. Blood 126(23):25, 2015.
95. Claussen CM, Chuang T, Shah J, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas SK, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, and Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23):5390, 2015.
96. San Miguel J, Maria-Victoria Mateos M-V, Shah JJ, Ocio EM, Rodriguez-Otero P, Reece D, Munshi NC, Avigan D, Ge Y, Balakumaran A, Marinello P, Orlowski RZ, and Siegel D. Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. Blood 126(23):505, 2015.
97. Yan X. Clemens PL, Puchalski T, Lonial S, Lokhorst HM, Orlowski RZ, Losic N, Khan I, Jansso R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, and Xu S. Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. Blood 126(23):4222, 2015.
98. Vogl DT, Raje NS, Jagannath S, Richardson PG, Hari P, Orlowski RZ, Supko J, Tamang D, Jones SS, Wheeler C, Markelewicz Jr. RJ and Lonial S. Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). Blood 126(23):1827, 2015.
99. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee HC, Orlowski RZ, Sarbassov DD, Neelapu SS, McDonnell TJ, Miranda RN, Wang M, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response. Blood 126(23):2051, 2015.
100. Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Ramos CB, Wang M, Romaguera J, Fayad LE, Orlowski RZ, Medeiros J and Fowler N. Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). Blood 126(23):2700, 2015.
101. Shah JJ, Feng L, Manasanch EE, Weber D, Thomas SK, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz SC, Landry A, Mendoza K, Champlin RE, Qazilbash MH, and Orlowski RZ. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 126(23):187, 2015.
102. Zhang X, Lu J, Qian Y, and Orlowski RZ. Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma. Blood 126(23):917, 2015.
103. Lee HC, Wang H, Lin H, Baladandayuthapani V, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, O'Brien S, Keats JJ, Yang J, Davis RE, and Orlowski RZ. RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma. Blood 126(23):3010, 2015.
104. Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, and Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126(23):3194, 2015.
105. Siegel DSD, Moreau P, Avigan D, Anderson KC, Reece DE, San Miguel J, Mateos M-V, Wu D, Emancipator K, Dolled-Filhart M, Gause C, Brown H, Heath K, Iannone R, Rose S, Orlowski RZ. A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 32(5s), 2014.
106. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. J Clin Oncol 32(5s), 2014.
107. Shi Q, Wang XS, Shah N, Orlowski RZ, Qazilbash MH, Williams LA, Mendoza TR, Cleeland CS. Prevalence of high symptom burden and its impact on functioning and quality of life in patients with multiple myeloma 3-9 months following autologous transplant. J Clin Oncol 32, 2014.
108. Qazilbash MH, Thall PF, Fox PS, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Valdez B, Parmar S, Dinh Y, Hosing C, Popat UR, Shah JJ, Orlowski RZ, Champlin RE. Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. J Clin Oncol 32(5s), 2014.
109. Usmani SZ, Hoering A, Sexton R, Ailawadhi S, Shah JJ, Fredette S, Durie BG, Zonder JA, Dhodapkar MV, Rajkumar SV, Mahindra AK, Zimmerman TM, Richardson PG, Orlowski RZ. SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). J Clin Oncol 32(5s), 2014.
110. Thomas SK, Melendez AG, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). J Clin Oncol 32(5s), 2014.
111. Thomas SK, Mendoza TR, Dougherty PM, Williams LA, Wang XS, Prasad S, Shah N, Shah JJ, Wang M, Weber DM, Orlowski RZ, Giralt S, Cleeland CS. A phase 2 trial of minocycline versus placebo to prevent neuropathy in patients (pts) with multiple myeloma (MM). J Clin Oncol 32, 2014.
112. Henderson MD, Kolonel LN, Anderson KC, Chiu B C-H, Zonder J, Orlowski RZ, Lonial S, Stram DO, Haiman C, Cozen W. Genetic Susceptibility Markers of Multiple Myeloma in African-Americans. Blood 651(2030), 2014.
113. Zhang Z-D, Yang J, Davis RE, Ma W, Wang Z, Yang L, Orlowski RZ,. Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity. Blood 651(3414), 2014.
114. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A. Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood 653(3448), 2014.
115. Usmani S, Fredette S, Durie B, Hoering A, Rajkumar SV, Richardson PG and Orlowski RZ. SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM). Blood 653(4762), 2014.
116. Shah N, Popat R, Hosing CM, Patel KK, Lin P, Shpall EJ, Orlowski RZ, Champlin RE and Qazilbash MH,. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. Blood 731(3981), 2014.
117. Shah JJ, Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, and Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 653(33), 2014.
118. Vogl D, Hari, MR, Jones SS, Supko JG, Leone G, Wheeler C, Orlowski RZ, Richardson PG, Lonial S, Tamang D, and Jagannath S. Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). Blood 653(4764), 2014.
119. Wang H, Wang HUA, Gu D, Zhong L, Ma W, Davis RE, and Orlowski RZ. Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma. Blood 605(274), 2014.
120. Mian I, Popat UR, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah JJ, Orlowski RZ, Qazilbash MH, Bashir Q and Champlin RE. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. Blood 731(194), 2014.
121. Yang J, Liu Z, Liu H, He J, Lin P, Orlowski RZ, Kwak LW, Tong Q, and Gagel R. Myeloma Cells Switch Osteoblastogenesis to Adipogenesis and Suppress Bone Formation. Blood 651(3386), 2014.
122. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T. Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood Oral Presentation 653, 2014.
123. Popat UR, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah JJ, Orlowski RZ, Qazilbash MH, Bashir Q and Champlin RE. Clinical Autologous Transplantation: Results: Clinical Results in Plasma Cell Dyscrasias 2. Blood 731, 2014.
124. Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, and Orlowski RZ,. Myeloma: Therapy, excluding Transplantation I. Blood 653, 2014.
125. Wang Hua, Gu D, Zhong L, Ma W, Davis RE, and Orlowski RZ. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Alternative Targets and Mechanism of Drug Resistance in Lymphomas and Myelomas. Blood 605, 2014.
126. Orlowski RZ. Phase II, randomized, double blind, placebo-controlled study with comparing siltuximab plus bortezomib versus bortezomib alone in patients with relapsed/refractory multiple myeloma. ASCO, 2013.
127. Wheeler C, Raje N, Mahindra A, Vogl D, Voorhees P, Bensinger W, Hari P, Berdeja J, Jagannath S, Jones S, Supko J, Orlowski RZ, Lonial S. New Drug Partner for Combination Therapy in Multiple Myeloma (MM): Development of Acy-1215, A Selective Histone Deacetylase 6 inhibitor alone and in combination with Bortezomib (B) or Lemalidomide (L). Submitted to EHA 2013, 2013.
128. San Miguel J, Blade J, Shpilbert O, Grosicki S, Maloisel F, Min C-K Mediavilla JD, robak T, Khuageva N, Prasad SV, Goh YT, Laubach J, Spencer A, Mateos M-V, Palumbo A, van de Velde H, Uhlar C, Qin X, Xie H, Orlowski R. Randomized, Open-Label, Phase 2 Study of Siltuximab (an Anti -L 6 MAB) and Bortezomib-Melphalan-Prednisone versus Bortezomib-Melphalan-Prednisone in Patients with Previously Untreated Multiple Myeloma. EHA, 2013.
129. Tunquist B, Brown K, Hingorani G, Aitchison R, Regensburger J, Lonial S, Kaufman J, Zonder J, Cohen A, Bensinger W, Orlowski R, Shah J, Hilder B, Ptaszynski M, Litwiler K, Walker D. Alpha 1-Acid Glycoprotein (AAG) is a Potential Patient Selection Biomarker for Improved Clinincal Activity of ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). Submitted to EHA 2013, 2013.
130. Dimopoulos MA. Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Anna Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H and Richardson PG. Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM). Blood 122(21):3177, 2013.
131. Orlowski RZ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM. Wang M, Holloway AN, Baladandayuthapani V, Lin JY, Fu M, Stellrecht CM, Morales de Partovi C, and Gandhi V. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). Blood 122(21):1953, 2013.
132. Hwang AE, Ailawadhi S, Bernal-Mizrachi L, Zimmerman TM, Haiman C, Van Den Berg DJ, Pawlish K, Mohrbacher AM, Terebelo H, Birmann BM, Stram DO, Conti DV, Janakiraman N, Henderson BE, Kolonel LN, Mehta J, Colditz GA, Graff JJ, Bock CH, Peters E, Chiu BC-H, Tomasson MH, Singhal S, Huff CA, Zonder JA, Orlowski RZ, Lonial S, and Cozen W. Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans. Blood 122(21):1872, 2013.
133. Zhang X-D, Baladandayuthapani V, Lin HY, Barlogie B, Usmani SZ, Yang L, and Orlowski RZ. Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma. Blood 122(21):123, 2013.
134. Alagappan A, Shah RA, Thomas SK, Weber DM, Michael Wang M, Alexanian A, Orlowski RZ, and Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood 122(21):1994, 2013.
135. Jones RJ, Kenney SC, Dawson C, and Orlowski RZ. Thalidomide, Lenalidomide and Pomalidomide Disrupt Epstein-Barr Virus (EBV) Latency: Clinical Implications. Blood 122(21):3499, 2013.
136. Patel K, Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski RZ, and Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 122(21):4310, 2013.
137. Lee HC, Wang H, Li B-Z, Wang Z, Jones RJ, Gu D, O'Brien S, Davis RE, and Orlowski RZ. CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models. Blood 122(21):4438, 2013.
138. Lonial S, Shah JJ, Zonder J, Bensinger WI, Cohen AD, Kaufman JL, Nooka AK, Weber DM, Hilder B, Rush SA, Ptaszynski A. Walker D, and Orlowski RZ. Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. Blood 122(21):285, 2013.
139. Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R. Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, and Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21):4396, 2013.
140. Pemmaraju N, Shah D, Kantarjian HM, Wagner V, Orlowski RZ, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour EJ, de Lima MJ, Champlin RE, Cortes JE, and Qazilbash MH. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood 122(21):1424, 2013.
141. Chen S, Dai Y, Zhang Y, Zhou L, Lin H, Pei X-Y, Orlowski RZ and Grant S. Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis. Blood 122(21):601, 2013.
142. Raje N, Vogl DT, Hari PN, Jagannath S, Jones SS, Supko JG, Leone G, Wheeler C, Orlowski RZ, Richardson PG, and Lonial S. ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). Blood 122(21):759, 2013.
143. Yang J, Zhong Y, He J, Liu Z, Liu H, Lin P, Orlowski RZ, and Kwak LW. Regulation Of DKK-1 Expression By p38 MAPK Signaling Via CREB Myeloma Cells. Blood 122(21):1917, 2013.
144. Thakurta A, Gandhi AK, Waldman M, Bjorklund C, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ Madan A, Ning Y, Mendy D, Lopez-Girona A, Schafer PH, Avet-Loiseau H, and Chopra R. Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance. Blood 122(21):3139, 2013.
145. Corrales-Medina FF, Bejar DEE, Manton C, Johnson B, Irwin ME, Orlowski RZ and Chandra J. Unique Apoptotic Effects Of Panobinostat and Marizomib In Acute Myeloid Leukemia and Bortezomib-Resistant Models. Blood 122(21):3837, 2013.
146. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger W, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Orlowski RZ, Kim EL, Bialas N, Smith DD, and Durie BGM. Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma. Blood 122(21):690, 2013.
147. Wang H, Baladandayuthapani V, Wang Z, Jiexin Zhang J, Lin HY, Davis RE, Yang L, and Orlowski RZ. Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor. Blood 122(21):2520, 2013.
148. Shah JJ, Feng L, Thomas SK, Weber DM, Wang M, Hilder B, Alexanian R, and Orlowski RZ. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood 122(21):1982, 2013.
149. Laubach JP, San Miguel JF, Sonneveld P, Orlowski RZ , Moreau P, Rosiñol L, Moslehi JJ, Faber Jr. EA, Voorhees PM, Marquez L, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine D-L, Niculescu L, Anderson KC, Lonial S, and Richardson PG. Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). Blood 122(21):3187, 2013.
150. Zhang X-D, Baladandayuthapani V, Lin HY, Barlogie B, Usmani SZ, Yang L, and Orlowski RZ. Identification Of Tight Junction Protein (TJP)-1 As a Modulator and Biomarker Of Proteasome Inhibitor Sensitivity In Multiple Myeloma. Blood 122(21):123, 2013.
151. Yang J, Xu J, Liu Z, He J, Liu H, Lin P, Orlowski RZ, Kwak LW, and Yi Q. Activation Of Autophagy By Bone Marrow Adipocytes Protects Myeloma Cells From Chemotherapy-Induced Apoptosis. Blood 122(21):1915, 2013.
152. Nusrat M, Kazmi SM, Cornelison AM, Kebriaei P, Nieto Y, Oran B, Orlowski RZ, Simrit Parmar S, Popat UR, Shah JJ, Shah N, Champlin RE, Qazilbash MH and Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 122(21):3358, 2013.
153. Shah RA, Mohite S, Baladandayuthapani V, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Popat UR, Champlin RE, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski RZ, and Shah JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood 122(21):5356, 2013.
154. Li B, Wang H, and Orlowski RZ. Proteasome Maturation Protein (pomp) Is Associated With Proteasome Inhibitor Resistance In Myeloma, and Its Suppression Enhances The Activity Of Bortezomib and Carfilzomib. Blood 122(21):280, 2013.
155. Gu D, Wang H, Wang Z, Davis RE, Cai S, Seki T, Tse A, and Orlowski RZ. The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma. Blood 122(21):1927, 2013.
156. Kongtim P, Qazilbash MH, Shah JJ, Orlowski RZ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin RE and Parmar S. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. Blood 122(21):3341, 2013.
157. Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, and Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood 122(21):3346, 2013.
158. Orlowski R, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos M-A, Cavenagh J, Spicka I, Maiolino A, Komarnicki M, Suvorov A, Blade J, Samoilova O, van de Velde H, Bandekar R, Kranenberg B, Xie H, Rossi J-F. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Comparing Siltuximab + Bortezomib vs. Bortezomib Alone in Pts with Relapsed/Refractory Multiple Myeloma. J Clin Oncol, 2012.
159. Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Rajangam K, Wear S, Orlowski RZ, and Siegel DS. PX-171-003-A1, an Open-label, Single-arm Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma: Long-term Follow-up and Subgroup Analysis. ISH, 2012.
160. Siegel DS, Martin T, Singhal S, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Kunkel L, Rajangam K, Chang Y-L, Orlowski RZ, Stewart AK and the MMRC. Patients refractory or intolerant to both bortezomib and immunomodulators show similar overall response rates to other clinically relevant subgroups in the single agent carfilzomib trial PX-171-003-A1. ASCO 2012, 2012.
161. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Kunkel L, Rajangam K, Chang Y-L, Wear S, Orlowski RZ, Stewart AK. Exploratory analysis of treatment-refractory subgroups from the single-agent carfilzomib trial PX-171-003-A1 in patients with relapsed and refractory multiple myeloma. Lymphoma & Myeloma 2012 Conference in New York, 2012.
162. Shah JJ, Orlowski RZ, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Popat UR, Parmar S, Shah N, Bashir Q, Champlin RE, and Weber DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood (ASH Annual Meeting Abstracts) 120(75), 2012.
163. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Orlowski RZ, Kim EL, McKinley MB, and Durie BGM. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(74), 2012.
164. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C, Harvey RD, Gleason C, Casbourne D, Nooka AK, Heffner LT, Richardson PG, Orlowski RZ, and Lonial S. Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. Blood (ASH Annual Meeting Abstracts) 120(336), 2012.
165. Tunquist B, Brown K, Hingorani G, Lonial S, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Orlowski RZ, Shah JJ, Hilder B, Ptaszynski AM, Koch K, Litwiler K, and Walker D. Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts) 120(1868), 2012.
166. Shah JJ, Zonder JA, Cohen A, Bensinger W, Kaufman JL, Orlowski RZ, Harvey RD, Abidi MH, Thomas SK, Walker D, Hilder B, Ptaszynski AM, and Lonial S. The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 120(449), 2012.
167. Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, and Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4082), 2012.
168. Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian A, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, and Orlowski RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4081), 2012.
169. Glitza IC, Lu G, Chen S, Orlowski RZ, and Qazilbash MH. C-MYC Rearrangement: A Marker for High-Risk Myeloma. Blood (ASH Annual Meeting Abstracts) 120(4989), 2012.
170. Parmar S, Howell J, Wang M, Khan MA, Bashir Q, Shah JJ, Shah N, Popat UR, Giralt SA, Orlowski RZ, and Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood (ASH Annual Meeting Abstracts) 120(750), 2012.
171. Shah JJ, Hegde A, Zhou X, Thomas SK, Wang M, Weber DM, Alexanian R, Orlowski RZ, and Vadhan-Raj S. Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE. Blood (ASH Annual Meeting Abstracts) 120(2244), 2012.
172. Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, Fu M, Stellrecht CM, Morales de Partovi C, Gandhi VV, and Orlowski RZ. Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(2976), 2012.
173. Gu D, Jones RJ, Wang H, Leopold L, and Orlowski RZ. Inhibition of the HDM-2 E3 Ligase Induces Types I and II Cell Death in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically in Both with ABT-737. Blood (ASH Annual Meeting Abstracts) 120(2940), 2012.
174. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale <, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, and Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(3707), 2012.
175. Fowler NH, Neelapu SS, Hagemeister Fb, McLaughlin P, Kwak LK, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, and Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstracts) 120(901), 2012.
176. Kuiatse I, Thomas SK, Weber DM, Stein AM, Wang M, Shah JJ, Treon SP, Ansell SM, and Orlowski RZ. Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 120(3723), 2012.
177. Patel K, Orlowski RZ, Shah N, Bashir Q, Parmar S, Dinh YT, Rondon G, Giralt SA, Champlin RE, and Qazilbash M. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(3115), 2012.
178. Weiss M, Jacobus S, Abonour R, Anderson KC, Barlogie B, Callander N, Gorak EJ, Hoering A, Kane RC, Katz MS, Matous J, Mills GM, Omel J, Orlowski RZ, Rajkumar SV, Richardson PG, Jensen LA, Little RF, Gertz MA, and Munshi NC. Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials. Blood (ASH Annual Meeting Abstracts) 120(3165), 2012.
179. Zhang X-D, Orlowski RZ, and Yang L. Identification of Tight Junction Protein (TJP)-1 As a Modulator of Sensitivity to Doxorubicin and Cisplatin in Models of Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 120(3962), 2012.
180. Cozen W, Hwang AE, Ailawadhi S, Singhal S, Huff CA, Bernal-Mizrachi L, Chiu BC-H, Brown EE, Peters E, Pawlish K, Mohrbacher A, Bock CH, Haiman C, Stram DO, Rand KA, Tomasson MH, Jain N, Van Den Berg DJ, Graff JJ, Colditz GA, Zimmerman TM, Zonder J, Orlowski RZ, and Lonial S. Explaining the Excess Risk of Multiple Myeloma in African-Americans. Blood (ASH Annual Meeting Abstracts) 120(4002), 2012.
181. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, and Yang J. P38 MAPK Activity in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction in Vivo. Blood (ASH Annual Meeting Abstracts) 120(566), 2012.
182. Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG, Stephenson P, Jones SS, Wheeler C, and Lonial S. Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. Blood (ASH Annual Meeting Abstracts) 120(4061), 2012.
183. Thomas SK, Delasalle KB, Shah JJ, Wang L, Orlowski RZ, and Weber DM. Impact of Rituximab On the Treatment of Waldenström's Macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts) 120(2734), 2012.
184. Kuhn DJ, Wang H, Jones FJ, Bjorklund CC, and Orlowski RZ. Blockade of IGF-1R with OSI-906 Overcomes Bortezomib-Resistance in Multiple Myeloma. Blood 118:925. e-Pub 2011.
185. Vij R, Kaufman JL, Jakubowiak AJ, Wang M, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch AR, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Wear S, Kunkel L, Wong AF, Lee P, and Stewart K. Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood 118:813. e-Pub 2011.
186. Bjorklund CC, Aukerman SL, Lopez-Girona A, Hussein M, Chopra R, Kuiatse I, Kuhn DJ, Wei C, and Orlowski RZ. Targeting the Wnt/β-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma. Blood. e-Pub 2011.
187. Zhu YX, Braggio E, Shi C-X, Schmidt J, Bruins L, Schuster SR, Fonseca R, Bergsagel PL, Bjorklund CC, Orlowski RZ, and Stewart AK. Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide. Blood 118:127. e-Pub 2011.
188. Munker R, Setoyama T, Duvic M, Orlowski RZ, and Calin G. Regulation of Selected MicroRNAs in Multiple Myeloma. Blood 118:3916. e-Pub 2011.
189. Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, and Hurd DD. Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study. Blood 118:3985. e-Pub 2011.
190. San Miguel JF, Richardson PG, Orlowski RZ, Goldschmidt H, Corzo D, Satler C , Esseltine D-L, Neuwirth R, Ponsillo M, Cakana AZ, King J, Deraedt WM, Desai A, Lutska Y, Gifkins D, Liu K, and Sonneveld P. Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). Blood 118:2933. e-Pub 2011.
191. Lonial S, Cohen A, Zonder J, Benzinger WI, Kaufman JL, Orlowski RZ, Harvey RD, Alexanian R, Thomas SK, Weber D, Walker D, Hilder B, Ptaszynski A, and Shah JJ. The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood 118:2935. e-Pub 2011.
192. Shah JJ, Zonder J, Cohen A, Orlowski RZ, Alexanian R, Thomas SK, Weber D, Kaufman JL, Harvey RD, Walker D, Litwiler K, Karan S, Hilder B, Ptaszynski AM, and Lonial S. ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. Blood 118:1860. e-Pub 2011.
193. Jakubowiak AJ, Siegel DS, Singhal S, Martin T, Lonial S, Kukreti V, Bahlis N, Chanan-Khan AA, Alsina M, Somlo G, Buadi FK, Reu FJ, Song KW, Kunkel L, Wear SM, Wong AF, Orlowski RZ, Stewart AK, Jagannath S, and Wang L. Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood 118:1875. e-Pub 2011.
194. Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, and Jagannath S. Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood 118:1876. e-Pub 2011.
195. Wang XS, Shi Q, Cleeland CS, Mendoza TR, Williams L, Joy J, Ilagan VM, Mobley GM, Gilmore KR, and Orlowski RZ. Development of Patient-Reported Bortezomib-Induced Peripheral Neuropathyin Multiple Myeloma Patients Undergoing Induction Therapy. Blood 118:677. e-Pub 2011.
196. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Mattar BI, Safah HF, Holmberg L, Dean RM, Orlowski RZ, and Barlogie B. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. Blood 118:2004. e-Pub 2011.
197. Ahmed S, Dinh YT, Qureshi S, Rondon G, Bashir Q, Parmar S, Avery T, Orlowski RZ, Champlin R, Qazilbash M, and Shah N. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. Blood 118:2017. e-Pub 2011.
198. Patel K, Orlowski RZ, Shah N, Bashir Q, Dinh YT, Rondon G, Giralt S, Champlin R, and Qazilbash MH. Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome. Blood 118:4522. e-Pub 2011.
199. Jones RJ and Orlowski RZ. Drug Resistance to the HDM-2 Inhibitors MI-63 and Nutlin Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA. Blood 118:2726. e-Pub 2011.
200. Kumar S, Lee JH, Lahuerta JJ, Morgan GJ, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hullin C, Klein SK, Sonneveld P, Siegel DS, Bladé J, Goldschmidt H, Jagannath S, San Miguel JF, Orlowski RZ, Palumbo A, Sezer O, Rajkumar SV, and Durie BGM. Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. Blood 118:3989. e-Pub 2011.
201. Glitza IC, Lu G, Chen Su, Orlowski RZ, and Qazilbash M. Clinical Features of Patients with Multiple Myeloma and C-MYC Rearrangements. Blood 118:5090. e-Pub 2011.
202. Ahmed S, Lin H, Baladandayuthapani V, Khan MA, Lu G, Rondon G, Qureshi S, Dinh YT, Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Champlin R, and Qazilbash MH. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 118:333. e-Pub 2011.
203. Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, De Lima M, Champlin R, and Giralt S. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood 118:4108. e-Pub 2011.
204. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, and Qazilbash MH. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 118:4156. e-Pub 2011.
205. Yang L, Zhang X, Wang H, Orlowski RZ, and Huang X. Validation of Potential Chemosensitivity Genes in Multiple Myeloma. Blood 118:1818. e-Pub 2011.
206. Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski RZ, Shah J, Alexanian A, Thomas S, Qazilbash M, Badilo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen, L. Electroacupuncture is an effective therapeutic modality for bortezomib- or thalidomide-induced peripheral neuropathy in patients with multiple myeloma and mantle cell lymphoma: A pilot study. 2011 International Myeloma Workshop, 2011.
207. Martin T, Siegel DS, Wang M, Vij R, Lonial S, Kukreti V, Bahlis N, Alsina M, Somlo G, Buadi F, Reu F, Song K, Kunkel L, Wong A, Vallone M, Orlowski R, Stewart AK, Singhal S, Jakubowiak AJ, the Multiple Myeloma Research Consortium (MMRC), Jagannath J.. Results of PX-171-003-A1, an open-label, single-arm, phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM). 2011 International Myeloma Workshop, 2011.
208. Wang M, Stewart AK, Kaufman JL, Jakubowiak AJ, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DH, Orlowski RZ, Kunkel LA, Le MH, Lee P, Rosen P, Sebag M, Vij M, and The Multiple Myeloma Research Consortium (MMRC).. Carfilzomib (CFZ) produces a high single agent response rate with minimal neuropathy even in relapsed multiple myeloma (MM) patients (pts) with high-risk disease. 2011 International Myeloma Workshop, 2011.
209. Kuhn DJ, Bjorklund CC, Wang M, Huo Y, and Orlowski RZ. Bortezomib resistance is mediated by increased signaling through cancer Osaka thyroid (Cot) kinase. 2011 International Myeloma Workshop, 2011.
210. Yong K, Orlowski R, Cavet J, Cole C, Davies F, Wlliams C, Akinaga S, Francis G, Rao N, Cavenagh J. Phase 1/2 trial of KW-2478 plus bortezomib in patients with relapsed/refractory multiple myeloma: results from the phase 1 portion. 2011 International Myeloma Workshop, 2011.
211. Zhu YX, Braggio E, Shi C-X, Schmidt JE, Bruins LA, Fonseca R, Bergsagel PL, Kuhn D, Orlowski R, and Stewart AK. Cereblon (CRBN) is a requirement for the anti-myeloma activity of thalidomide, lenalidomide and pomalidomide. 2011 International Myeloma Workshop, 2011.
212. Richardson P, Orlowski R, San Miguel J, Niesvizky R, Attal M, Baz R, Brandenburg N, Lonial S, Bensinger W. Risk of second primary malignancies (SPM) in relapsed/refractory multiple myeloma (RRMM) patients (pts) treated with lenalidomide and dexamethasone (LEN+DEX): analysis of MM-009/010 SPM incidence rate (IR). 2011 International Myeloma Workshop, 2011.
213. Morgan G, Durie B, San Miguel J, Orlowski R, Lonial S, Palumbo(6) Niesvizky AR, Baz R, Giralt S, Bensinger W, Brandenburg NN, Yu Z, Boccadoro M, Richardson P, Anderson K,. Retrospective analysis of the long term safety of lenalidomide (LEN) +/- dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM). 2011 International Myeloma Workshop, 2011.
214. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, and Weber D. The regimen of lenalidomide (len), thalidomide (thal), and dexamethasone (dex) is active against relapsed and/or refractory multiple myeloma (RRMM) and overcomes lenalidomide resistance. 2011 International Myeloma Workshop, 2011.
215. Siegel DSD, Martin T, Wang M, Vij R, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Somlo G, Buadi F, Reu FJ, Song KW, Kunkel LA, Wong A, Vallone M, Orlowski RZ, Stewart AK, Singhal S, Jagannath S, Jakubowiak AJ. PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. J Clin Oncol 29. e-Pub 2011.
216. Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Lacerte L, Fowler NH. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 29. e-Pub 2011.
217. Durie BG, Morgan G, San-Miguel JF, Orlowski RZ, Lonial S, Niesvizky R, Yu Z, Anderson KC. Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. J Clin Oncol 29. e-Pub 2011.
218. Dimopoulos MA, Orlowski RZ, Niesvizky R, Lonial S, Brandenburg NA, Weber DM. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. J Clin Oncol 29. e-Pub 2011.
219. Orlowski RZ, Wang XS, Mendoza TR, Williams LA, Johnson VE, Joy J, Ilagan V, Mobley GM, Liu P, Gilmore KR, Cleeland CS. Prevalence and trajectory of disease- and treatment-related symptom burden in patients with multiple myeloma undergoing induction therapy. J Clin Oncol 29. e-Pub 2011.
220. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Patterson M, Harvey D, Berger AJ, McDonald A, Mulligan G, Boral A, Pickard MD, Smith PG, Kuan HS, Walker R, Garnsey J, Burke K, Lonial S. MLN4924, a novel investigational NEDD8-activating enzyme (NAE) inhibitor, in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL): Phase 1 dose-escalation study. 15th Congress of EHA, 2010.
221. Reed VK, Shah JJ, Mazloom A, Weber DM, Phan J, Orlowski RZ, Thomas SK, Wang M, Alexanian R, Dabaja BS. Outcome and prognostic factors in solitary plasmacytoma. American Society of Clinical Oncology 45th Annual Meeting 28(15):May 20 supplement, 2010.
222. Bensinger W, Wang M, Orlowski RZ, Alsina M, Martin T, Singhal S, Gabrail Y, Vallone M, Kauffman M and Niesvizky R. Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). American Society of Clinical Oncology 45th Annual Meeting, 2010.
223. Siegel SD diC, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, Lonial S, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer E, Wong AF, Vallone M, Chang Y-L, Kauffman M, Orlowski RZ, Stewart AK, Singhal SB and the MMCR. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood 116, 2010.
224. Martin T, Singhal SB, Vij R, Wang M, Stewart AK, Jagannath S, Lonial S, Jakubowiak AJ, Kukreti V, Bahlis NJ, Alsina M, Chanan-Khan AA, Somlo G, Buadi F, Reu FJ, Zonder JA, Song K, Stadtmauer EA, Wong AF, Vallone M, Chang Y-L, Kauffman M, Orlowski RZ and Siegel DS diC. Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): Results of a subset analysis of a phase 2 trial in patients with relapsed and refractory multiple myeloma (RRMM). Blood 116, 2010.
225. Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, McDonagh KT, Alsina M, Bahlis NJ, Belch A, Reu FJ, Gabrail NY, Matous J, Vesole DJ, Orlowski RZ, le MH, Lee P, Wang M, and the MMRC. Carfilzomib: High single agent response rate with minimal neuropathy even in high-risk patients. Blood 116, 2010.
226. Singhal SB, Siegel DS diC, Martin T, Vij R, Wang M, Jakubowiak AJ, Lonial S, Kukreti V, Zonder JA, Wong AF, McCulloch L, Kauffman M, Badros AZ, Niesvizky R, Orlowski RZ, Stewart AK and Jagannath S. Pooled safety analysis from phase (Ph) 1 and 2 studies of carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (MM). Blood 116, 2010.
227. Shah JJ, Zonder JA, Cohen A, Weber D, Thomas S, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Rush SA, Ptaszynski A, Orlowski RZ and Lonial S. A phase I/II trial of the KSP inhibitor ARRY-520 in relapsed/refractory multiple myeloma. Blood 116, 2010.
228. Jakubowiak AJ, Martin T, Singhal SB, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Bray L, Vallone M, Kauffman M, Orlowski RZ, siegel DS diC and The MMRC. Responses and survival are not affected by cytogenetics in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent carfilzomib. Blood, 2010.
229. Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore M, Strader J, Orlowski RZ and Hurd DD. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. Blood 116, 2010.
230. Shah JJ, Harvey DR, O'Connor OA, Jakubowiak AJ, Smith MR, Orlowski RZ, Mulligan GJ, Smith PG, Pickard MD, Dezube BJ and Lonial S. Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and/or refractory multiple myeloma or lymphoma. Blood 116, 2010.
231. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U and Weber D. Phase I trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood 116, 2010.
232. Kaufman JL, Shah JJ, Laubach JP, Heffner L, Francis D, Harvey RD, Lewis C, Tighiouart M, Richardson P, Orlowski RZ and Lonial S. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Initial results of a phase 1 study. Blood 116, 2010.
233. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE and Qazilbash MH. Outcome of high dose melphalan with autologous hematopoietic stem cell transplant in myeloma associated with AL amyloidosis. Blood 116, 2010.
234. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE and Qazilbash MJ. High dose melphalan with autologous stem cell transplantation overcomes poor prognosis of primary amyloidosis. Blood 116, 2010.
235. Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, Laubach J, Moreau P, Morgan G, Orlowski, RZ, Palumbo A, Richardson P, San Miguel JF, Sezer O, Siegel D, Sonneveld P, Szymonifka J, Rajkumar SV, Durie BGM. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Blood 114(2878), 2009.
236. Delasalle KB, Wang L, Weber D, Giralt SA, Thomas S, Shah J, Handy B, Orlowski RZ, Alexanian R. Curability of multiple myeloma. Blood 114(3864), 2009.
237. Jakubowiak A., Wang L, Orlowski RZ, Jagannath S, Siegel D, Stewart AK, Kukreti, V, Lonial S, McDonagh DT, Vallone M, Kauffman M, Vij R, The Multiple Myeloma Research Consortium (MMRC). Influence of cytogenetics in patients with relapsed and refractory multiple myeloma (MM) treated with carfilzomib (CFZ). Blood 114(1827), 2009.
238. Wang L, Siegel D, Kaufman JL, Stewart AK, Jakubowiak AJ, Alsina M, Kukreti V, Bahlis NJ, McDonagh KT, Belch A, Sebag M, Gabrial N, Le MH, Bennett MK, Kunkel L, Kauffman M, Orlowski RZ, Vij R, The Multiple Myeloma Research Consortium (MMRC). Updated results of bortezomib-naive patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood 114(302), 2009.
239. Siegel D, Wang L, Orlowski RZ, Kaufmann JL, Stewart AK, Kukreti V, Alsina M, Jakubowiak, AJ, Jagannath S, McDonagh KT, Belch A, Bahlis NJ, Shustik C, Le MH, Kunkel L, Bennett MK, Kauffman M, Vij R, The Multiple Myeloma Research Consortium (MMRC). PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood 114(303), 2009.
240. Trudel S, Lee S, Kirk CJ, Gabrail N, Lonial S, Wang L, Orlowski RZ, Kukreti V, Stewart AK, Jagannath S, McDonagh KT, Buadi F, Zonder JA, Bennett MK, The Multiple Myeloma Research Consortium (MMRC). Inhibition of the proteasome in bone marrow-derived CD 138+ tumor cells following carfilzomib administration in relapsed or refractory myeloma patients. Blood 114(1845), 2009.
241. Niesvizky R, Wang L, Orlowski RZ, Bensinger W, Alsina M, Gabrail N, Gutierrez A, Kunkel L, Kauffman M, The Multiple Myeloma Research Consortium (MMRC). Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 114(304), 2009.
242. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival disparities between African-American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Blood 114(1395), 2009.
243. Dai Y, Chen S, Pei X-Y, Ramakrishnan V, Wang M, Orlowski R, Dent P, Grant S. Targeting CDK9 dramatically potentiates ABT-737-induced apoptosis in human multiple myeloma cells through a Bim-dependent mechanism. Blood 114(297), 2009.
244. Vij R, Wang L, Orlowski RZ, Stewart AK, Jagannath S, Lonial S, Trudel S, Jakubowiak AJ, Belch A, Alsina M, Bahlis NJ, Le MH, Cruickshank S, Bennett MK, Molineaux S, Kauffman M, Siegel D, The Multiple Myeloma Research Consortium (MMRC). Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood 114(430), 2009.
245. Vij R, Wang M, Orlowski RZ, Stewart AK, Jagannath S, Kukreti V, Le MH, Kunkel L, Siegel D. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. Am Soc Clin Oncol 45 Annual Meeting, 2009.
246. Shah N, Weber D, Orlowski R, Wang M, Thomas SK, Richards T, Giralt S, Qazilbash M, Alexanian R, Shah JJ. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. Am Soc Clin Oncol 45th Annual Meeting(8596), 2009.
247. Bjorklund CC, Kuhn DJ, Matthews JA, Wang M, Baladandayuthapani V, Orlowski RZ. Activation of the Wnt/β-Catenin pathway mediates lenalidomide resistance in multiple myeloma. Blood 114(113), 2009.
248. Kuhn DJ, Bjorklund CC, Magarotto V, Matthews JA, Wang M, Balandandayuthapani V, Orlowski RZ. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1/Akt axis. Blood 114(2739), 2009.
249. Hunsucker SA, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 sensitizes plasma cell dyscrasias to the effects of melphalan in association with suppression of signaling through protein kinase B/Akt. Blood 114(1836), 2009.
250. Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Dodd A, Foster MC, Gabriel DA, Shea TC, Serody J, van Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study. Blood 114(306), 2009.
251. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable remission with salvage autotransplants in patients with multiple myeloma. Blood 114(1227), 2009.
252. Zangari M, Polavaram L, Zhan F, Tricot GJ, Ravi V, Jagannath S, Siegel D, Stewart AK, Wang, L, Orlowski RZ, Belch A, Jakubowiak AJ, Somlo G, Trudel S, Bahlis NJ, Lonial S, Singhal S, Kukreti V. Alkaline phosphatase (ALP) variation during carfilzomib treatment is associated to best response in multiple myeloma. Blood 114(2865), 2009.
253. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Patterson M, Harvey D, Berger AJ, McDonald A, Mulligan G, Petruzzelli L, Pickard MD, Smith PG, Venkatakrishnan K, Lonial S. Phase 1 dose-escalating study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. Blood 114(1854), 2009.
254. Thomas SK, Feng L, Delasalle KB, Wang M, Shah JJ, Orlowski RZ, Alexanian R, Weber DM. Prognostic factors for survival after 2-CdA-based therapy for symptomatic Waldenström macroglobulinemia (M) stratify patients into low- and high-risk groups. Blood 114(1668), 2009.
255. Magarotto V, Londhe A, Lantz KC, Lowery C, Sonneveld P, Blade J, Harousseau J-L, Orlowski RZ. Impact of Baseline Free Light Chair Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal DOxorubicin Plus bortezomib or Bortezomib Alone. Blood 114(4778), 2009.
256. San Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Blade J, robak T, Mndle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® and VELCADE® in previously treated myeloma patients aged ≥65 years. Intl Soc Oncol Pharmacy Practitioners XI/Hematology/Oncology Pharmacty Association 2008 Joint Annual Symposium, 2008.
257. Spencer A, Hajek R, Nagler A, Sonneveld P, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® and VELCADE® in previously treated high risk myeloma. Int'l Soc. Onc. Pharmacy Practitioners XI/Hematology/Oncology Pharmacy Association 2008 Joint Annual symposium, 2008.
258. Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, Hennessey K, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Int'l Soc Onc Pharmacy Practitioners XI/Hematology/Oncology Pharmacy Association 2008 Joint Annual Symposium, 2008.
259. O'Connor OA, Goy A, Orlowski R, Hainsworth JD, Leonard JP, Afanasyev B, Osmanov D, Chen M, Wolff A. A Phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. J Clin. Oncol 26(8539):463s, 2008.
260. Voorhees PM, Manges R, Sonneveld P, Somlo G, Jagannath S, Zweegman S, Munteanu M, Vermeulen JT, Xie H, Orlowski RZ. Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). J. Clin. Oncol(4903):301b, 2008.
261. Blade J, Sonneveld P, San Miguel J, Sutherland H, Hajek R, Nagler A, Spencer A, Robak T, Harousseau JL, Orlowski RZ. The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal impairment. J Clin Oncol 26(8562):469s, 2008.
262. Yang L, Orlowski RZ. ZKSCAN3, a novel zinc finger transcription factor, regulates Cyclin D2 expression in multiple myeloma (MM) cells. Blood 112(749), 2008.
263. Vij R, Wang M, Orlowski RZ, Stewart AK, Jagannath S, Kukreti V, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D, and The Multiple Myeloma Research Consortium (MMRC). Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood 112(865), 2008.
264. Jones RJ, Arts J, Orlowski RZ. Inhibition of the human double minute (HDM)-2 E3 ubiquitin ligase activates different programmed cell death (PCD) pathways in models of non-Hodgkin lymphoma (NHL) with wild type (wt) and mutant (mut) p53. Blood 112(3618), 2008.
265. Cole, SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MJ. Reduced-intensity regimens for allogeneic stem cell transplantation improve the outcome in advanced multiple myeloma. Blood 112(3298), 2008.
266. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, Giralt SA. A randomized phase II trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma. Blood 112(3320), 2008.
267. Rossi J-F, Manges RF, Sutherland HJ, Jagannath S, Voorhes P, Sonneveld P, Delforge M, Pegourie B, Alegre A, de la Rubia J, La Police D, Bandekar R, Xie H, Orlowski RZ. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 112(867), 2008.
268. Pamarthi V, Kuhn DJ, Voorhees PM, Strader JS, Orlowski RZ, Chen Q. Kinesin spindle protein inhibition for the treatment of multiple myeloma. Blood 108(1435):124a, 2007.
269. Stewart AK, O'Connor, OA, Alsina M, Trudel S, Urquilla PR, Vallone MK, Molineaux CJ, Goy A, Orlowski RZ. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 25(8003):441s, 2007.
270. Harousseau J-L, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, Robak T, Xiu L, Zhuang SH, Orlowski RZ, for the DOXIL-MMY-3001 study investigators. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol 25(8002):441s, 2007.
271. Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, Zhunang SH, Harousseau J-L, Fruchtman S, Orlowski RZ for the DOXIL-MMY-3001 study investigators. Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 25(8023):446s, 2007.
272. Jones RJ, Leopold L, Yang D, Orlowski RZ. Targeting the human double minute (HM)-2 p53 ubiquitin ligase as a strategy against non-Hodgkin lymphoma. J clin Oncol 25(14016):613s, 2007.
273. San Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated myeloma patients aged ≥65 years. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece 92 (s2)(620):159, 2007.
274. Spencer A, Hajek R, Nagler A, Sonneveld P, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated high risk myeloma. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (s2)(629):162, 2007.
275. Nagler A, Hajek R, Sonneveld P, Spencer A, Blade J, Robak T, Mundle SD, Zhuang SH, Harousseau J-L, Orlowski RZ. DOXIL® + VELCADE® in previously treated myeloma patients with prior stem cell transplant. Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (s2)(625):161, 2007.
276. Alsina M, O'Connor OA, Stewart AK, Trudel S, Urquilla PR, Vallone MK, Molineaux CJ, Goy A, Orlowski RZ. Clinical responses in multiple myeloma and Waldenström's macroglobulinemia with the proteasome inhibitor carfilzomib (PR-171). Haematologica (XIth International Workshop on Multiple Myeloma, Kos, Greece) 92 (S2)(611):156, 2007.
277. Orlowski RZ, Sutherland HJ, Blade J, San-Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Robak T, Mundle SD, Luo D, Zhuang SH, Harousseau JL. Early normalization of serum free light chain is associated with prolonged time to progression following bortezomib ± pegylated liposomal doxorubicin treatment of relapsed/refractory multiple myeloma. Blood 110(2735):803a, 2007.
278. Manges RF, Sutherland HJ, Jagannath SJ, Orlowski RZ, La Police D, DeWitte M, Lang Z, Corringham RE, Rossi JF. Preliminary results of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb), in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 110(1183):358a, 2007.
279. Sutherland HJ, Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, O'Neal W, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. Effect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin + bortezomib vs. bortezomib alone in relapsed/refractory multiple myeloma. Blood 110(2740):805a, 2007.
280. Blade J, San-Miguel JF, Nagler A, Sonneveld P, Spencer A, Robak T, Hennessey K, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Blood 110(410):127a, 2007.
281. O'Connor O, Goy A, Orlowski RZ, Hainsworth J, Leonard J, Afanasyev B, Osmanov D, Reyno LM, Chen MM, Escandon R. A phase I-II study to determine the safety, pharmacokinetics and potential efficacy of intravenous administration of SB-743921 on days 1 and 15 of 28 day dosing schedule in patients with non-Hodgkin's lymphoma. Blood 110(2556):753a, 2007.
282. Orlowski RZ, Stewart AK, Vallone MK, Molineauz CJ, Kunkel L, Gericitano J, O'Connor OA. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (R-171) dosed for five consecutive days in hematologic malignancies: Phase I results. Blood 110(409):127a, 2007.
283. Kumar S, Blade J, San-Miguel JF, Hajek R, Nagler A, Sonneveld P, Spencer A, Sutherland HJ, Robak T, Mundle SD, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin in combination with bortezomib may provide therapeutic advantages for high-risk multiple myeloma patients who relapse within 12 months of stem cell transplant. Blood 110(2730):802a, 2007.
284. Chen Q, Esseltine D-L, Neuwirth RB, Richardson PG, Orlowski RZ. Ciprofloxacin inhibits bortezomib-mediated apoptosis in multiple myeloma models in association with induction of heme oxygenase-1. Blood 110(2365):698a, 2007.
285. Weaver JA, Brannen C, DeSimone J, Orlowski RZ. Novel nanoparticle-based approaches to target B-cell malignancies. Blood 110(4903):301b, 2007.
286. Jones RJ, Yang D, Bruey-Sedano N, Orlowski RZ. Targeting the human double minute (HDM)-2 p53 ubiquitin ligase as a strategy against non-Hodgkin lymphoma. Blood 110(1374):413a, 2007.
287. Euliss, L.E., DuPont, J.A., Welch, C.M., Pisano, E., Lin, W., Small, G.W., Orlowski, R.Z., Serody, J., Hahn, K.M., and DeSimone, J.M.. Utilizing the emerging imprint lithography technique (PRINT) for the fabrication of shape-specific organic nanoparticles for applications in nanomedicine. American Chemical Society 232nd National Meeting, 2006.
288. DuPont, J.A., Euliss, L.E., Orlowski, R.Z., Serody, J., Hahn, K.M., Welch, C.M., Small, G.W., Ferrer, I., and DeSimone, J.M.. Applying imprint lithography (PRINT) for the generation of shape-specific, targeted nanocarriers in medicine. American Chemical Society 232nd National Meeting, 2006.
289. Orlowski, R.Z.. Targeting the ubiquitin-proteasome pathway for treatment of malignant lymphomas: Bortezomib and beyond. 12th Danish Cancer Society Symposium, 2006.
290. Kurzrock R, Voorhees P, Fayad L, Orlowski R, VanRhee F, Furman R, Borghaei H, Zaki M, Prabhakar U, Garay C. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies. J Clin Oncol 24(2513):103S, 2006.
291. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ. Extended follow-up of outcome measures and analysis of prognostic factors in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. J Clin Oncol 24(7617):450S, 2006.
292. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, Kurzrock R. CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) - Preliminary results of subjects with Castlemans disease from a phase 1 study in selected hematological malignancies. Blood 108(2728):771a, 2006.
293. Orlowski RZ, Chanan-Khan AA, Zehngebot LM, Watson PR, Peterson BL, Sanford BL, Caligiuri MA, Kelly M, Larson RA for the Cancer and Leukemia Group B. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood 108(797):239a, 2006.
294. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Orlowski RZ. The novel, irreversible proteasome inhibitor PR-171 demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma, and overcomes bortezomib resistance. Blood 108(3461):987a, 2006.
295. Chen Q, Pamarthi V, Kuhn DJ, Voorhees PM, Strader JS, Orlowski RZ. Inhibition of kinesin spindle protein induces apoptosis and overcomes drug resistance in models of multiple myeloma. Blood 108(3425):978a, 2006.
296. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Mendy D, Lopez-Girone A, Plantevin V, Xu W, De Parseval L, Corral LG, Glezer E, Chan K, Mercurio F, Orlowski RZ. Targeting the p27 Kip1 E3 ubiquitin ligase for the treatment of multiple myeloma and other hematological malignancies. Blood 108(372):114a, 2006.
297. Kuhn DJ, Voorhees PM, Chen Q, Strader JS, Bruzzese F, Ciavarri JP, Hu Z, Orlowski RZ. Development of immunoproteasome-specific inhibitors as novel anti-cancer drugs. Blood 108(3458):986a, 2006.
298. Voorhees PM, Small GW, Kuhn DJ, Chen Q, Hunsucker SA, Corringham R, Garay CA, Zaki MH, Nemeth J, Orlowski RZ. Enhancing activity of bortezomib against multiple myeloma (MM) through inhibition of interleukin (IL)-6 signaling: A role for repression of myeloid cell leukemia (Mcl)-1. Blood 108(3414):975a, 2006.
299. Voorhees PM, Small GW, Kuhn DJ, Chen Q, Hunsucker SA, Coringham R, Garay, CA, Zaki MH, Nemeth J, Orlowski RZ. CNTO328 abrogates glucocorticoid (GC) resistance conferred by interleukin (IL)-6 and the bone marrow microenvironment in multiple myeloma (MM). Blood 108(3473):990a, 2006.
300. O'Connor OA, Orlowski RZ, Alsina M, Stewart AK, Trudel S, Vallone MK, Woo TM, Urquilla PR, Molineaux CJ, Goy A. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies. Blood 108(2430):687a, 2006.
301. Orlowski RZ, Zhuang SH, Parekh T, Xiu L, Harousseau J-L for the DOXIL-MMY-3001 study investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase III study. Blood 108(404):124a, 2006.
302. Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA. Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301. Haematologica 90(s1):151, 2005.
303. Kuhn DJ, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Orlowski RZ. Potent activity of a novel, irreversible inhibitor of the ubiquitin-proteasome pathway against pre-clinical models of multiple myeloma. Blood 106:452a, 2005.
304. Voorhees PM, Kuhn DJ, Small GW, Strader JS, Corringham R, Zaki MH, Nemeth J, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO328 sensitizes multiple myeloma cells to bortezomib and attenuates proteasome inhibitor-mediated induction of the anti-apoptotic heat shock protein response. Blood 106:452a, 2005.
305. Orlowski RZ, Kuhn DJ, Small GW, Michaud C, Orlowski M. Identification of novel inhibitors that specifically target the immunoproteasome, and induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems. Blood 106:76a, 2005.
306. Orlowski RZ, Shi YY, Small GW. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 88(1)(9):S31, 2004. PMID: 17483361.
307. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Siegel D, Irwin D, Schuster M, Srkalovic G, Orlowski RZ, Esseltine D, Wen P, Amato A, Anderson KC. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE®). The SUMMIT and CREST Study Group. Hematol J 5(2):S129, 2004.
308. Orlowski RZ, Voorhees PM, Garcia RA, Hall M.D., Adams, J., Esseltine, D.L., Gabriel, D.A., Shea, T.C., Deventer, H.W. Van, Mitchell, B.S., and Dees, E.C. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Hematol J 5(2):S131, 2004.
309. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Hideshima T, Esseltine D-L, Anderson KC. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: An update with additional follow-up. Hematol J 5(2):S103, 2004.
310. Orlowski RZ, Small GW, Shi YY. 16th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics. Eur J Cancer 2:17, 2004.
311. Fried DB, Morris DE, Shea TC, Orlowski RZ, Van Deventer HW, Mitchell BS. A systematic review evaluating the addition of radiation therapy to chemotherapy for localized aggressive non-Hodgkin’s lymphoma: What is the role for radiotherapy. Blood 104:862a, 2004.
312. Orlowski RZ. The ubiquitin-proteasome pathway as a target for breast cancer therapy. Breast Cancer Res Treat 88(1):S4, 2004.
313. Orlowski RZ, Shi YY, Small GW. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Breast Cancer Res Treat 88(1):S31, 2004.
314. Orlowski RZ, Voorhees PM, Garcia RA, Hall, MD, Hogan CM, Kudrik FJ, Humes E, Johri A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine, D-L, Depcik-Smith ND, Bell H, Lehman MJ, Dees, EC. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Hematology J 4:S254, 2003.
315. Dees EC, O’Neil B, Humes E, Hall M, Carey L, Collichio F, Graham M, Orlowski RZ. Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc Amer Soc Clin Oncol 22:217, 2003.
316. Jagannath S, Richardson P, Barlogie B, Berenson J, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine D, Anderson K Other authors: Traynor A, Vincent Rajkumar V, Alsina M, Siegel D, Alexanian R, Orlowski RZ, Schuster M, Kuter D, Limentani S, Richards G, Adams J. Phase II trial of bortezomib in combination with dexamethasone in multiple myeloma: Assessment of additional benefits in patients with non-optimal responses. Proc Amer Soc Clin Oncol 22:528, 2003.
317. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Esseltine D, Schenkein DP, Anderson KC Other Authors: Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Richards G, Adams J. Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma treated with bortezomib. Proc Amer Soc Clin Oncol 22:581, 2003.
318. Lee S, Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Schenkein D, Esseltine D, Anderson K, Other authors: Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Richards G, Adams J. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma treated with bortezomib. Proc. Amer. Soc. Clin. Oncol 22:582, 2003.
319. Orlowski RZ, Voorhees P, Garcia R, Hall M, Adams J, Esseltine D, Dees EC. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Proc Amer Soc Clin Oncol 22:200, 2003.
320. Jagannath S, Richardson P, Barlogie B, Berenson J, Singal S, Siegel D, Irwin D, Schuster M, Rajkumar V, Alexanian R, Srkalovic G, Limentani S, Alsina M, Orlowski RZ, Esseltine D, Anderson K. Results of two multicenter Phase II trials using the proteasome inhibitor bortezomib in relapsed and/or refractory multiple myeloma. Hematol J, 2003.
321. Orlowski RZ. Targeting the proteasome in cancer therapy. Int J Mol Med 12:S61, 2003.
322. Orlowski RZ. Bortezomib-based combination regimens in multiple myeloma. Cancer Invest 22, 2003.
323. Dees EC, O’Neil BH, Humes EW, Carey LA, Collichio F, Johri A, Graham ML, Orlowski RZ. A Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin. Breast Cancer Res Treat 82(1):84, 2003.
324. Jagannath S, Barlogie B, Berenson J, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Nix D, Guerciolini R, Esseltine D, Anderson KC. Limited experience from two Phase 2 trials suggests bortezomib can be given safely in multiple myeloma patients with severe renal impairment with comparable responses and toxicities. Blood 102:236a, 2003.
325. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar V, Limentani S, Alsina M, Orlowski RZ, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, Anderson KC. Peripheral neuropathy following bortezomib (VELCADE™, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): Characterization and reversibility. Blood 102:149a, 2003.
326. Orlowski RZ, Voorhees P, Garcia R, Hall M, Lehman M, Johri A, Humes E, Adams J, Esseltine D, Gabriel D, Shea T, van Deventer H, Mitchell B, Dees EC. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 102:449a, 2003.
327. Perrot A, Facon T, Usmani S, Plesner T, Orlowski R, Touzeau C, basu S, Bahlis N, Goldschmidt H, O'Dwyer M, Venner CP, Weisel K, Hulin C, Karlin L, Clalit M, Broyl A, Renwick W, Hansson M, Krevvat M, Wang JI, rampel RV, Kropec JU, Uhlar C, Kobos R, Kumar S. UPDATED ANALYSIS OF DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE-NDMM): THE PHASE 3 MAIA STUDY. COMy 2021 virtual congress.
328. Dang M, Qin L, Tan W, Dong L, Lee HC, Patel KK, Moreno Ruedo LY, Lin P, Bansal H, Berrios D, Thomas SK, Weber DM, Symer DE, Wang L, Manasanch EE, Orlowski RZ.. Single cell profiling of BCMA naïve vs refractory relapsed myeloma patients reveals unique transcriptomic profiles in tumor and microenvironment. Blood 651(publication number 3169).

Book Chapters

1. Lee HC, Orlowski RZ. Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. In: Resistance to Proteasome Inhibitors in Cancer. Springer: New York, 81-98, 2014.
2. Orlowski RZ. Novel Proteasome Inhibitors. In: Advances in Biology and Therapy of Multiple Myeloma. Springer: New York, 157-180, 2013.
3. Shah JJ and Orlowski RZ. Bortezomib in relapsed and relapsed/refractory multiple myeloma. In: Bortezomib in the Treatment of Multiple Myeloma. Springer Publishing: Basel, Switzerland, 79-94, 2010.
4. Orlowski RZ and Gabriel DA. Multiple myeloma. In: Netter's Internal Medicine. 2nd Edition. Icon Publications: Teterboro, NJ, 541-546, 2009.
5. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. In: Annu Rev Pharmacol Toxicol, 189-213, 2006.
6. Kuhn DJ, Zeger EL and Orlowski RZ. Proteasome inhibitors and modulators of heat shock protein function. In: Updates on Cancer Therapeutics. Elsevier, 91-116, 2006.
7. Orlowski RZ. Proteasome inhibitors in cancer therapy. In: Methods Mol Biol, 339-350, 2005.
8. Orlowski RZ. Targeting the proteasome in cancer therapy. In: Apoptotic pathways as targets for novel therapies in cancer and other diseases. Kluwer Academic Publishers: Norwell, MA, 243-274, 2005.
9. Orlowski RZ. Anthracyclines and bortezomib. In: Proteasome Inhibitors in Cancer Therapy. Humana Press Inc: Totowa, NJ, 171-180, 2004.
10. Orlowski RZ. Current concepts in the initial management of patients with multiple myeloma. In: American Society of Clinical Oncology 2004 Educational Book. American Society of Clinical Oncology: Alexandria, VA, 441-447, 2004.
11. Orlowski RZ. The ubiquitin-proteasome pathway and breast cancer. In: Breast Cancer Molecular Oncology. Jones and Bartlett: Boston, MA, 373-393, 2004.
12. Orlowski RZ. Malignant lymphomas. In: Netter's Internal Medicine. Icon Publications: Teterboro, NJ, 411-415, 2003.
13. Harvey D and Orlowski RZ. Multiple myeloma. In: M.D. Anderson Colormatrix Staging and Treatment Handbook. Textbook. Kluwer Academic Publishers: Norwell, MA.

Letters to the Editor

1. Orlowski RZ. Incorporating real-world evidence and patient value criteria into value-based frameworks for relapsed/refractory multiple myeloma. J Manag Care Spec Pharm 24: 487, 2018.